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1. INTRODUCTION 
1.1. Flow cytometry 
Flow cytometry (FCM) is an indispensable tool for diagnosis, classification, staging and 
monitoring of hematological malignancies (1,2). Improvements in FCM instrumentation and 
the availability of an expanded range of antibodies and fluorochromes render it an optimal 
tool for the study of other difficult biological and diagnostic issues. Recent refinements and 
improvements in FCM technology have provided new investigative approaches and improved 
accuracy in the diagnosis of hematological neoplasms (1,2). However, the application of this 
technique to the diagnosis and clinical research of non-hematological cancers, e.g., in effusion 
cytology, still requires improvement in way of optimization and calibration, due to the 
different characteristics of epithelial cells compared to lymphoid cells. Multiparameter FCM 
immunophenotyping is a suitable method in terms of rapidity, sensitivity, reproducibility and 
reliability for measurement of cellular antigens, including those located in the cytoplasm, 
nucleus, and cell surface. This technology allows simultaneous measurement and 
quantification of various cellular attributes, contributing to an accurate definition of antigen 
profiles on diverse cell populations.  
 
1.1.1 The principles of FCM 
FCM is a technology for measuring various properties of cells, cell organelles, and other 
objects suspended in liquid and flowing at rates of several thousand per second through a flow 
chamber in which a technique called hydrodynamic focusing organizes the cells into a single 
stream. This stream then passes through the point of interrogation, in which the cells can be 
exposed to a number of lasers with different wavelengths (3-11).  
The applications of FCM are diverse and can be used to investigate whole cells and some of 
the cellular components, such as DNA, RNA, nuclear antigens, enzymes, surface antigens, 
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etc. Theoretically, any constituent of a cell to which a fluorescent dye can bind is measurable. 
The important feature is that measurements are made on single cells, individually.  
A flow cytometer is composed of three major subsystems, which cooperate to simultaneously 
measure multiple physical characteristics of single cells/particles, as shown diagrammatically 
in Figure 1.  
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Figure 1. Diagrammatic representation of the three major subsystems in a flow cytometer. 
 
1.1.2 The fluidics subsystem 
The important task of the fluidics subsystem is to bring and center cells/particles in the 
illuminating beam. The flow chamber is the main component of the fluidics subsystem where 
the cells in suspension are slowly injected (inlet stream) into a faster flowing system of fluid 
(sheath fluid), providing a “laminar sheath” that surrounds the cells or particles (Figure 2). 
When the circumstances are right, sample fluid (the inlet stream) is confined to the central 
core of the laminar flow entering the interrogation point. This process is called hydrodynamic 
focusing. It stabilizes and narrows the sample stream containing cells through the 
interrogation point, where the cells intersect with excitation sources (3-9,11). The sample and 
sheath fluid streams may be driven by air pressure, by vacuum or by pumps. The majority of 
commercial flow cytometers use a closed flow chamber and air pressure (7,9,10). The overall 
velocity of the cell suspension through the chamber is determined by the pressure setting use 
to drive the sheath fluid. If the flow rate of the sheath fluid increases without a change in the 
core flow rate, the core diameter becomes smaller and the cells move faster. Conversely, if the 
sheath flow rate decreases without a change in the core flow rate, the core diameter becomes 
larger and the cells move slower (4,7,11). The flow rate of the cells passing the illumination 
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beam depends on the velocity of the sheath fluid stream, the diameter of the sample core, and 
the concentration of cells in the suspension.  In most commercial flow cytometers the sheath 
flow rate can be adjusted. At a given laser beam size, the lower the flow rate, the more times 
each cell will be excited and the more light will be collected leading to increase the 
sensitivity. However, extended dwell time in the laser beam may result in significant 
photobleaching of many fluorochromes (4,7,11).  
 
 
 
 
 
 
 
 
 
Figure 2.  The Flow Chamber in which the cells in suspension are slowly injected (inlet stream) into a 
faster flowing system of fluid (sheath fluid), providing a “laminar sheath” surrounding the cells. 
 
1.1.3 The optics subsystem 
The optics subsystem is composed of excitation sources and components to collect light 
signals and direct them to the suitable detectors (Figure 1). 
 
1.1.3.1 The excitation sources 
Most current flow cytometers utilize lasers as light sources to illuminate a cell/particle that 
has been hydrodynamically focused by the fluidics system (Figure 1). The reason for using 
lasers is due to their ability to provide a narrow, intense beam of monochromatic light that can 
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be focused by a lens to a small point (interrogation point). Cells/particles in a sample stream 
can flow rapidly through this interrogation point receiving an adequate amount of illumination 
during their short time of exposure in a laser beam to generate scatter and fluorescence light 
of detectable intensity. The large majority of modern flow cytometers are equipped with more 
than one laser (up to four or more). The most commonly utilized laser is an argon ion laser 
configured to produce light at 488 nm wavelength. Due to the increasing demand for a wide 
array of fluorochomes, an increase in the number of lasers (helium-neon, violet, red diode, 
etc.) on flow cytometers is required (3-11).  
 
1.1.3.2 Measurement of light signals 
When a cell/particle intersects a laser beam, it scatters and emits light in all directions (360°). 
The optical subsystem is responsible for collecting light signals and routing them to the 
appropriate detectors. Two types of light scattering properties are measured in two directions. 
One is over a narrow angle in the forward direction, and second is at right angle to the laser 
beam by a photodiode and photomultiplier tube (PMT), respectively (3-7,11). These devices 
convert the light signal to an electrical signal that can be processed by the data processing and 
analysis unit. 
The wavelength of the scattered light is the same as the incident light, and the laser light 
scattered by a cell/particle depends on its size and other properties. Scatter light 
characteristics yield valuable information about the sample and can be used to discriminate 
between different cellular subpopulations (e.g. lymphocytes, monocytes and granulocytes), 
cells from debris, viable cells from dead cells, and single cells from clusters of cells. The 
amount of light scattered over a narrow angle at approximately 0.5° to 10.0° in the forward 
direction is detected in the forward scatter channel (FSC). The intensity of forward scatter is 
proportional to the size, shape and optical homogeneity of cells, size being the predominant 
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parameter. The forward scatter gives strong signal that can be detected by a photodiode, 
which translates FSC light into electrical pulses. The electrical pulses are amplified and 
digitalized for storage in a computer. 
The amount of light scattered to the side (perpendicular to the axis of the laser light, 90°) is 
detected in the side or right angle light scatter channel (SSC). The intensity of side scatter is 
proportional to the size, shape and optical homogeneity of cells, optical homogeneity being 
the predominant parameter (Figure 3). Side scatter signals are relatively weak and need to be 
amplified by a PMT, which converts SSC light to an output signal current and digitized for 
storage in a computer (3,4,11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic diagram of a flow cytometer with FSC and SSC detectors. 
 
1.1.3.3 Fluorescent emission  
Fluorescence (property of emitting electromagnetic radiation as a result of absorption of 
radiation [photons] by an atom, molecule or ion) (12) occurs when fluorochrome-labeled 
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cells/particles are excited by a laser beam of a certain wavelength (electrons can only remain 
in excited state for a few nanoseconds) returns to the unexcited (ground) state by emitting 
light of a longer wavelength (Figure 4) (3,12). The major advantage of using fluorochromes 
for FCM is their sensitivity. By combining high power lasers, efficient light-collecting optics 
and sensitive PMT a few thousand fluorochromes per cell can be specifically detected. Thus 
FCM is able to demonstrate or quantify low amounts of cellular macromolecules. In FCM, in 
addition to light scatter, one or more fluorescence signals are usually measured. The 
fluorescent light is collected at right angles to the laser beam. Most current laboratory flow 
cytometers are equipped with two or more lasers and are able to measure four or more 
fluorochromes simultaneously (13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The absorption and emission of light during fluorescence.  
Fluorescent molecule absorbs energy as photons, which increases the energy level of its electrons. 
However, when the molecule returns to ground state, it emits light (photons) of a longer wavelength than 
the excitation wavelength. 
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1.1.3.4 The optical subsystem 
The optical system of a flow cytometer is responsible for collecting and quantifying the 
scatter light and emitted fluorescence. The different types of fluorescent emission - green, 
yellow, red and deep red - and the scattered light are collected and separated from one another 
by using networks of dichroic mirrors, beam splitters and optical filters, which can direct the 
emitted light with certain wavelength toward specific optical filters, before it can be detected 
by the PMTs and converted to electrical signals (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Optical layout.  
Both side scatter light signal and fluorescence light signal are collected simultaneously through the same  
collector lens, The composite light signal has to be separated in its individual component by using dichroic 
mirrors, beam splitter and filters, before it can be detected by the PMT. 
 
In flow cytometers with more than one laser, the laser beams are separated in a way that a cell 
flows through each laser beam within a few microseconds. Thus the signals are separated in 
time, making it easier to resolve them.  
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Each of the fluorescent channels is configured to measure a narrow range of wavelengths. 
PMTs are located at the end of each light path and are designated as FL1, FL2, FL3 and FL4 
for detection of the green, yellow, red and deep red fluorescence, respectively. Each 
fluorochrome does not emit a single wavelength of light, but a broad spectrum of light. In 
single color analysis, fluorescence signal is detected in one channel corresponding to the 
wavelength emitted by the fluorochrome. In multicolor analysis with two or more different 
fluorochromes, problems with emission spectra overlaps occur and fluorescence signal from a 
single labeled cell/particle may be detected in two different channels, leading to false-positive 
results. To partly solve the emission spectra overlaps, band pass (transmitting a specific 
narrow band of wavelengths) are placed in front of each PMT in order to reduce spectral 
overlap. In principle, more lasers, detectors and different optical filters can be configured to 
make even more measurements on each cell, with the limitation being the number of dye 
combinations that can be used (3,4,6,11).   
 
1.1.4 The electronic subsystem 
The main function of the electronic subsystem is to convert scatter and fluorescence light 
signals to electronic signals, which are then digitized and further processed into numerical 
data. Data for each cell/particle will be stored in the computer for further analysis. 
 
The main components of electronic circuitry of a flow cytometer are shown in Figure 6. 
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Figure 6. A schematic diagram of the electronic circuitry of a flow cytometer. 
 
1.1.4.1 Signal processing 
Photodetectors detect photons of light and produce electrical current. The electrical current is 
converted to a voltage by a preamplifier, which produces a voltage pulse that is proportional 
in size to the number of photons that originally reached the detector (4).  
Threshold setting 
Pulses are generated when cells/particles flow through a laser. In order to avoid collection of 
data on debris or noise in the system, a threshold (a minimum of pulse high for signals to be 
processed) can be applied on the output voltage so that only signals above a certain limit are 
processed. Signals below threshold are not processed and no data are acquired for those 
events (Figure 7-A). It is set by the operator, usually on the FSC parameter. Figures 7- B, 7-
C and 7-D show an example of the threshold setting after the signals are digitized and further 
processed into numerical data and transferred to the computer. If the threshold is set too low, 
small signal events such as debris and noise will be included (Figure 7-B). If the threshold is  
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set too high, relevant cells will be excluded from the analysis (Figure 7-D) (3,4,11,14,15).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The threshold setting. The discriminator (dash line) has been set on FSC parameter. The 
example above illustrates that (A) only the signals above the threshold will be recorded (dashed line). In 
(B) the cells of interest (gray) have been recorded together with some debris and noise (black dots).  In (C) 
the threshold is set correctly and the debris and noise has been excluded. In (D) the discriminator has 
been set too high resulting in exclusion of some of the cells of interest. 
 
Pulse quantification 
Signal processors measure voltage pulses providing numerical values for the total integrated 
signal, width of the signal and peak height of the signal as pulse area, width and height, 
respectively (Figure 8) 
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Figure 8. Signal processing results in pulse quantification. The output voltage pulse can be proportional to 
the width of the signal, the height of the signal, or the integrated area of the signal.  
 
Amplifiers 
Flow cytometers are equipped with two types of amplifier, which are capable of amplifying 
the integrated area of the signal, width of the signal, or the peak of the signal either linearly or 
logarithmically. The output voltage in linear amplification is directly proportional to the input 
voltage. Linear amplification is useful for measurement of populations with narrow dynamic 
range, such as measurement of DNA for cell cycle analysis. The gain of the linear amplifier 
can be adjusted. 
A logarithmic amplifier displays the output voltage proportional to the logarithmic of the 
input signal. Logarithmic amplification is useful for the measurement of populations with 
wide dynamic range, as in immunofluorescence. In comparison to a linear amplifier, a 
logarithmic amplifier has a wider dynamic range and expands the scale of weak signals and 
contracts the scale of strong signals. For example, at a given linear amplifier setting, two 
signals with intensities of 100 and 200 will have the same voltage distance away from each 
other as two signals with intensities of 800 and 900. In contrast to a log amplifier at a given 
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setting, two signals with intensities of 100 and 200 (twofold increase in intensity) will have 
twofold longer distance away from each other than two signals with intensities of 800 and 900 
(1.125-fold increase in intensity). Most flow cytometers are equipped with four-decade full 
scale logarithmic amplifier, because this range is useful for several proteins on cell 
membrane. Cells labeled with fluorochrome-conjugated antibody are normally 10 to 1000 
times as bright as unlabeled cells (3,4,11,14,15). 
 
Analogue-to-digital converter (ADC) 
The last signal processing step is analog-to-digital conversion. The ADC converts the output 
of the analog signal into a digital signal for further processing and storage. Most flow 
cytometers apply 10-bit ADCs, which have 2
10
 or 1024 separate bins or channels and the 
signals can have a range values from 0 to 1023 (3,4,20,14,15). 
 
1.1.4.2 Emission spectral overlaps 
Compensation is a process to correct multi-color FCM data for emission spectral overlaps, 
which occur between different fluorochromes used for measuring cellular components and 
represent the biggest problem when performing multi-color FCM analysis (Figure 9). This 
overlap is a consequence of the use of fluorochromes that are measurable in more than on 
detector. In order to reduce the spectral overlaps, one can use dyes with different absorption 
optima, which are excited by two or more sequentially positioned laser beams of different 
wavelengths. As illustrated in Figure 10, a cell/particle passes the red laser beam first and 
then, few microseconds later, the blue laser beam. Thus, the signal excited by the red laser is 
delayed and separated in time from the blue excited signals. The laser time delay is adjusted 
to ensure that the signals are contributed to the correct event. However, the majority of the 
fluorescent dyes suitable for FCM, e.g., Fluorescein isothiocyanate (FITC) and R-
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phycoerythrin (RPE), are excited by the same laser line, and fluorescence signals therefore 
cannot be separated in time. Using suitable optical band pass and long pass filters (Figure 5), 
most of the emission spectral overlaps can be minimized. However, some overlaps still 
remain (Figure 9) and the contribution of signal in detectors not assigned to that 
fluorochrome must be subtracted from the total signal in those detectors. This process is 
termed “compensation” and can be shown by two commonly used fluorochromes: FITC and 
RPE. As shown in Figure 9 FITC fluorescent signal (green) is detected using a 530/30 nm 
band pass filter and the RPE fluorescent signal (orange) is measured through a 585/42 nm 
band pass filter. Both FITC and RPE emit some orange and green fluorescence, respectively, 
and these signals cannot be eliminated by optical filters. Hence, some of the green fluorescent 
signals will be detected by the PMT applied for detection of RPE fluorescent signals, whereas 
the PE fluorescent signals will be detected by the PMT used for detection of FITC fluorescent 
signals (Figure 9).  
This undesirable spectral “spillover” (Figure 11-A) could be erroneously interpreted, as 
emission from the orange fluorochrome (RPE) is present on the green fluorochrome (FITC 
only)-labeled cell population, and the green fluorescent signal is present on the orange 
fluorescence-labeled (RPE only), as illustrated in Figure 11-A, marked II and III, 
respectively. The problem of unwanted spectral overlap can be overcome by using either 
hardware (after signal detection but before logarithmic conversion and digitization) or 
software (post-collection) compensation or both compensation strategies in a multi-color 
setup. The leakage of the orange fluorescence signal from FITC is electronically subtracted 
from the signal detected in orange fluorescence channel (Figure 11-B, II ) and the leakage of 
the green fluorescence signal from RPE is electronically subtracted from the signal detected in 
the FITC channel (Figure 11-B, III) (13,16,17).  
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Figure 9. Emission spectral overlaps of FITC, PE and peridinin chlorophyll protein (PerCP). 
 
 
 
 
 
 
 
 
 
 
Figure 10. Signal generation in time. A cell is simultaneously labeled with two or more fluorescent dyes 
that differ in both their absorption optimum and emission optimum, e.g. FITC and allophycocyanin 
(APC). First, the cell passes the red laser beam and the fluorescent dye APC, with an absorption optimum 
in the red range of the spectrum, is excited, and will thus emit fluorescence light. The FITC fluorescent 
 29 
dye is not excited, due to the large difference between the absorption wavelength of the dye and the 
excitation wavelength of the light source. The red-excited signal from APC is electronically delayed until 
the same cell passes the second laser beam (blue). At this point FITC is excited, whereas the red 
fluorescent dye APC is not, because of the large difference in absorption and excitation wavelength. The 
two signals will arrive at the analysis electronics at the same time and will be detected with separate 
PMT’s 
 
 
 
 
 
 
 
 
Figure 11. The correction of spectral overlap by electronic compensation. Ellipses and circles represent 
uncompensated and compensated cell populations, respectively. Cell populations I, II and III are isotype-, 
green fluorescence- and orange fluorescence-stained, respectively.   
In the uncompensated situation (Figure 11-A), one can observe using a green fluorescence vs. orange 
fluorescence dot plot that the isotype stained (background) cells (I) are located at the lower left quadrant.  
The green fluorescence positive cells (II) and the orange fluorescence (III) show a diagonal flattened 
distribution, owing to spectral overlaps of the green fluorescence signal into the orange fluorescence 
detector and the orange fluorescence signal into green fluorescence detector. Both green and orange 
spectral fluorescence overlaps (Figure 11-A, II and III) are greater than the background fluorescence of 
the isotype labeled cells (I). 
The correction is made by subtracting the unwanted amount of the green fluorescence signal from the 
signal in the orange fluorescence detector, as shown in Figure 11-B, marked II. When the mean/median 
value of the orange fluorescence of green fluorescence-positive cells is comparable to the mean/median 
value of the orange fluorescence of the isotype stained cells (dashed line), compensation is adequate.  
In figure 11-B, marked III, the unwanted contribution of the orange fluorescence to the green fluorescence  
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detector (III) is corrected. The mean/median value of the green fluorescence of the orange fluorescence-
positive population is comparable to that of the green fluorescence of the isotype stained cells (dot line). 
 
1.1.4.3 Data display 
The list mode data can be analyzed applying a computer and software. The software is often 
part of the same computer system used to control the instrument during acquisition of the 
specimens. External software provided by a third-party vendor can be used for data analysis, 
often with the possibility of post-collection compensation feature. The data presentation can 
be performed in different way by using various displays, including univariate histograms or 
correlated dot plots. A univariate histogram is often used for visualization of a single 
parameter FCM data. Cell number is displayed against intensity of the measured parameter 
(Figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 12. A histogram showing fluorescence against cell number. The signals from a wide distribution of 
fluorescence intensities are depicted on a logarithmic scale. The wide distribution reflects biological 
variability within a population. 
 
 31 
When two parameters are visualized at the same time, a correlated dot plot is applied; each 
single cell is depicted as a dot on the screen and shows the value of the two parameters 
measured (Figure 13).  
 
 
 
 
 
 
 
 
 
 
Figure 13.  Flow cytometers enable the simultaneous measurement of different parameters. Each dot on 
the quadrant R3 represents one cell that is labeled with Ber-Ep4 and Annexin-V-conjugated to a green 
fluorescence signal (FL1=FITC) and a far red fluorescence signal (FL4=APC), respectively.  
 
1.2. Ovarian cancer 
1.2.1. Epidemiology, etiology and pathogenesis 
Ovarian cancer is the eighth most commonly diagnosed cancer and the seventh leading cause 
of cancer death in women worldwide, comprising nearly 4% (225,500) of the total new cancer 
cases and 4% (140,200) of the total cancer deaths among females in 2008 (18). The incidence 
rates in economically developed countries are nearly twice as in economically developing 
counties, and mortality rates are 2% higher in more economically developed compared to less 
economically developed counties (18). From 1999-2008, a total of 4,570 new cases of ovarian 
cancer were recorded in Norway and the age-adjusted incidence rate ranged from 10.8 to 13.8 
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per 100,000 person-years (19). Despite moderate improvement, the prognosis of this disease 
is still poor, with a 5-year relative survival at about 44% in Norway in 2008 (19). The high 
fatality rate is mainly attributed to diagnosis at advanced stage (III-IV) based on the 1988 
International Federation of Gynecology and Obstetrics (FIGO) staging system (20). The 
majority of ovarian cancers are epithelial (ovarian carcinoma; OC) and afflict women near 
menopause or post-menopause, median age at diagnosis being between 60 and 65 years. 
Approximately 10% of women with OC have positive family history, whereas the remaining 
90% of cases are sporadic (21).  
 
Although the origin and evolution of OC remain largely unknown, several risk factors, 
including age, ovulation, reproductive history and genetic polymorphisms have been proposed 
to be predisposing factors (21-25). Age is an important risk factor for OC, as reflected in the 
high incidence of the disease in older women. Incessant ovulation, early age at menarche, late 
age of natural menopause and nulliparity are associated with increased risk for this disease. In 
contrast, there is evidence that the use of oral contraceptives and pregnancy reduce the risk of 
ovarian cancer considerably (21-25).  
Genetic abnormalities such as TP53 mutation with loss of p53 function are frequently found 
in both sporadic and familial OC cases. In addition, inheritance of DNA repair defects and 
mutations in the BRCA1 and BRCA2 genes increase the risk of developing this disease (21-
26). 
 
Recent morphologic and molecular genetic studies have suggested that OC develops de novo 
and that based on distinctive morphologic and molecular features, OC may originate from the 
fallopian tubes, uterus, cervix, and upper vagina which develop from the Müllerian duct of the 
embryo.  Thus, OC were divided in two groups, designated type I and type II tumors (22,27-
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29). Type I are slow-growing tumors which arise from borderline tumors and include low-
grade serous, low-grade endometrioid, clear cell, mucinous and transitional carcinomas. 
These tumors are genetically stable and lack TP53 mutations, although frequent mutations in 
the KRAS, BRAF, ERBB2, PTEN, CTNNB1 and PIK3CA genes occur. Conversely, type II 
tumors, comprising high-grade serous, high-grade endometrioid, malignant mixed 
mesodermal tumors (carcinosarcomas) and undifferentiated carcinomas, are fast-growing, 
highly aggressive tumors and often present at advanced stage at diagnosis. They are identified 
by genetic instability and display TP53 mutations in more than 80% of cases, as well as 
BRCA mutations and CCNE1 amplification, but rarely harbor the mutations observed in type I 
tumors (22,27-29). These findings may suggest that each type of OC develops along different 
molecular pathways. Other authors have suggested that the five major subtypes of OC (high-
grade serous, clear cell, endometrioid, mucinous and low-grade serous), which have different 
biomarker expression, are distinct disease entities (30).  
Until recently, it was widely accepted that OC arises in the ovarian surface epithelium or 
cortical inclusion cysts. Lately, this view of ovarian carcinogenesis has been challenged 
through morphological, immunohistochemical and molecular genetic studies suggesting that 
low-grade and high-grade serous ovarian carcinomas derive from the fallopian tube 
epithelium implanting on the ovary (29,31,32). 
 
1.2.2. Clinical features, classification and staging 
OC is an aggressive disease with a high mortality rate that reflects the fact that this tumor 
develops without an obvious symptom profile, rendering it difficult to diagnose at early stages 
and resulting in widespread disease at diagnosis. The symptoms of ovarian cancer are often 
vague and include abdominal pain or discomfort, bowel irregularity, persistent fatigue, weight 
loss, distended or tense abdomen, pain outside the abdominal cavity, frequent urination, and 
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respiratory difficulties (21,27,33). Women suffering from one or more of the aforementioned 
symptoms are likely to be referred to an internal medicine or general surgery unit instead of a 
gynecological unit, unlike women with symptoms such as vaginal bleeding or discharge, 
resulting in delayed diagnosis and treatment (33). During examination, physical findings 
typically include a palpable ovarian mass, in addition to an increase in abdominal girth as a 
result of ascites formation and dyspnea due to pleural effusion (21,27,28). Transvaginal 
ultrasonography (TVS) or computed tomographic (CT) is often carried out for further 
assessment of the pelvic mass, if OC is suspected on the basis of the above-mentioned 
findings. The presence of a complex ovarian mass with both solid and cystic components, 
sometimes with septations and internal echoes, is highly suggestive of OC. The occurrence 
and formation of ascites is suggestive of advanced disease and an exploratory laparotomy is 
usually done for histological confirmation, staging and tumor debulking (21,27,28).  
 
The symptoms of OC are often nonspecific. Thus, early detection might to a large extent 
improve survival, if discovery of the early lesions on routine physical examination can lead to 
surgery prior to metastasis and if tumors remain localized for a satisfactory interval to allow 
effective screening (21,27). Given its prevalence, strategies for early recognition of this 
disease must have a high sensitivity (>75%) for early-stage disease, and very high specificity 
(99.6%) to accomplish a positive predictive value of 10% or greater (21,27). Serum cancer 
antigen-125 (CA-125), TVS and a combination of both methodologies have been evaluated 
for their ability to detect OC at early stages. However, CA-125 level as a single marker in the 
screening test lacks sensitivity and specificity. Greater specificity can be achieved by 
combining CA-125 and TVS, by monitoring of CA-125 concentration over time, or both. The 
use of CA-125 with additional biomarkers in a panel might increase the sensitivity. 
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Development of sensitive and specific biomarkers based on different proteomic profiles has 
been suggested to be effective in early detection of OC (27).   
 
Classification of primary cancers of ovary is performed according to the structures of the 
ovary from which they are derived. Ovarian neoplasms are classified as surface epithelial 
tumors, sex cord-stromal tumors, germ cell tumors and secondary tumors (34). Most of the 
epithelial tumors are believed to develop from epithelial cells covering the ovary or lining 
inclusion cysts (21,34), and these cells are thought to derive from the coelomic epithelium of 
mesodermal origin. OC are the most common ovarian malignancies and account for 90% of 
all malignant ovarian neoplasms. OC is histologically categorized according to cell type into 
serous, mucinous, endometrioid, clear cell, transitional, squamous, mixed and undifferentiated 
(35,36). According to world Health Organization (WHO) classification based on microscopic 
evaluation of the amount of epithelial cell proliferation, the degree of nuclear atypia and the 
presence or absence of stromal invasion, tumors in each of these categories are further divided 
into benign, borderline and malignant forms (35,36). Serous tumors are the most frequent 
epithelial tumors, and are composed of cells ranging in appearance from those resembling the 
fallopian tube epithelium in well differentiated tumors to anaplastic cells in poorly 
differentiated tumors (34,35). The growth pattern of serous carcinoma varies from glandular 
to papillary to solid. OC is histologically graded 1 to 3, corresponding to well differentiated, 
moderately differentiated and poorly differentiated, respectively (35,37). 
 
OC spreads primarily by direct shedding of carcinoma cells throughout the peritoneal cavity 
forming ascites and multifocal tumor metastases to other peritoneal compartments/organs, 
including the urinary bladder, uterus, bowel, omentum, and mesocolic lymph nodes. The most 
frequent extra-abdominal site of distant metastasis is the pleural space, and distant metastasis 
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to the parenchyma of the liver, lungs, and other organs is less common (27).  Patients with 
early-stage OC (stages I-II) have long-term survival (>10 years) rates in the 80-95% range, 
whereas 75% of patients with advanced disease (stages III-IV) have low long-term survival 
rates, ranging from 10-30% (27). The spreading pattern of OC is reflected in the FIGO 
staging system, detailed in Table 1 (37).  
 
  Table 1. FIGO staging of OC (1988) (37) 
Stage I 
Ia 
 
Ib 
 
Ic
a
 
 
 
Stage II 
IIa 
IIb 
IIc
a
 
 
 
Stage III 
 
 
 
 
IIIa 
 
 
IIIb 
 
 
IIIc 
 
Stage IV 
 
Growth limited to the ovaries 
Growth limited to one ovary; no ascites present containing malignant cells. No 
tumor on the external surface; capsule intact 
Growth limited to both ovaries; no ascites present containing malignant cells. 
No tumor on the external surfaces; capsules intact 
Tumor either Stage Ia or Ib, but with tumor on surface of one or both ovaries, or 
with capsule ruptured, or with ascites present containing malignant cells, or 
with positive peritoneal washings 
Growth involving one or both ovaries with pelvic extension 
Extension and/or metastases to the uterus and/or tubes 
Extension to other pelvic tissues 
Tumor either Stage IIa or IIb, but with tumor on surface of one or both ovaries, 
or with capsule(s) ruptured, or with ascites present containing malignant cells, 
or with positive peritoneal washings 
Tumor involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
inguinal nodes. Superficial liver metastases equals Stage III. Tumor is 
limited to the true pelvis, but with histologically proven malignant 
extension to small bowel or omentum 
Tumor grossly limited to the true pelvis, with negative nodes, but with 
histologically confirmed microscopic seeding of abdominal peritoneal surfaces, 
or histologic proven extension to small bowel or mesentery 
Tumor of one or both ovaries with histologically confirmed implants, peritoneal 
metastasis of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; 
nodes are negative 
Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes 
Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to 
Stage IV. Parenchymal liver metastasis equals Stage IV. 
 
a
 In order to evaluate the impact on prognosis of the different criteria for allotting cases to 
Stage Ic or IIc, it would be of value to know if rupture of the capsule was spontaneous, or 
caused by the surgeon; and if the source of malignant cells detected was peritoneal washings 
or ascites 
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1.2.3. Treatment of OC 
Surgical treatment of OC may be adequate if the tumor is well-differentiated and confined to 
the ovary. For patients with advanced-stage OC, a combination of surgery followed by 
adjuvant chemotherapy is standard therapy. The type of surgical treatment depends upon 
disease stage, as well as tumor type and grade. Young women with early-stage (stage I), low-
grade disease, who wish to preserve their fertility, are treated by removal of the involved 
ovary (unilateral oophorectomy) (21,27,28). In advanced-stage disease, the surgical procedure 
includes a total abdominal hysterectomy, bilateral salpingo-oophorectomy along with 
examination of all peritoneal surfaces, omentectomy, peritoneal biopsies and retroperitoneal 
assessment involving both the pelvic and para-aortic area, as well as drainage of ascites or 
peritoneal washing (21,27,28). The aim of the initial surgical effort is to achieve optimal 
debulking. The most widely-accepted definition of optimal debulking has been residual tumor 
<1 cm in diameter (27,38). Several reports have shown that the volume of residual disease 
remaining after cytoreductive surgery inversely correlates with survival (reviewed in 38). In 
recent years, the definition of optimal debulking has changed to also include maximal 
debulking efforts, with the end goal of complete resection of all visible disease (27,38). On 
the basis of retrospective studies, the suggestion for complete resection of all visible disease is 
becoming more widely appreciated, as it has been documented to improve overall survival 
(OS) (38). 
 
In the majority of cases, adjuvant chemotherapy is a standard postoperative treatment 
(21,27,28). The first-line chemotherapy regimen for OC consists of paclitaxel in combination 
with a platinum-based compound (cisplatin or carboplatin) or platinum-based therapy only. In 
large randomized clinical phase III trials of advanced-stage OC, using cisplatin vs. carboplatin 
in combination with paclitaxel resulted in comparable results in term of patient survival. 
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However, a combination of carboplatin-paclitaxel was the preferable regimen due to less 
toxicity, superior quality of life, and easier administration (39-41). Despite the improvements 
in outcome provided by these therapy regimens, the preponderance of the women with 
advanced-stage OC will relapse and eventually die of their disease (41). As new 
chemotherapy compounds have been recognized and shown activity for recurrent disease, 
several approaches have been established to determine if additional cytotoxic agents such as 
gemcitabine, methoxypolyethylene glycosylated liposomal doxorubicin and topotecan in 
primary treatment would further improve progression-free survival (PFS) or OS. Interim 
analysis provided no benefit in survival of the patients (42-44). Hence, carboplatin-paclitaxel 
combination remains the standard front-line therapy.  
Since attempts to improve patient survival by adding other agents to the standard front-line 
therapy have yielded disappointing results, Katsumata et al. (45) have addressed the 
frequency of the treatment by performing a randomized phase III trial with dose-dense 
regimen of a weekly paclitaxel in combination with carboplatin every three weeks. Significant 
improvement in PFS and OS survival using this regimen was observed compared to the 
conventional regimen. However, toxicity related to hematological side effects was higher in 
the dose-dense group. 
 
Intraperitoneal (IP) treatment with platinum-based agents and taxanes has been shown to be a 
valuable regimen for standard care for advanced OC based on the leverage of 
chemotherapeutic agents and the delivery of high doses into the abdominal compartment in an 
attempt to maximize drug activity against OC (46-48). A number of studies have shown a 
benefit in terms of prolonged patient survival of IP treatment compared to single intravenous 
(IV) administration of chemotherapy for OC Patients (49-51). Armstrong et al. evaluated the 
efficacy of palitacxel and cisplatin as either an IV regimen only or as an IV/IP combination 
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for six cycles in optimally debulked stage III OC patients. Despite the fact that only 42% of 
patients in the IP group completed the six cycles of treatment, significant gain in PFS and OS 
was confirmed. The median PFS was 23.8 months in the IP arm and 18.3 months in the IV 
arm, whereas the OS for the IP arm and IV arm was 65.6 months and 49.7 months, 
respectively. Although this study revealed increased toxicity and reduced quality of life 
during treatment, the authors advocated the use of IP chemotherapy regimen as standard care 
for first-line treatment (46). However, the application of IP chemotherapy regimen as first-
line treatment has been hotly debated due to the toxicity, complication rate, methodological 
difficulties and variability in the study design related to IP drug administration (47,52-55). 
 
Neoadjuvant chemotherapy (NACT), defined as administration of platinum and taxane-based 
chemotherapy prior to debulking surgery, is playing an important role in patients with 
advanced OC for whom initial surgical treatment is not feasible (38,56). Reduction in 
morbidity applying NACT followed by interval debulking compared to initial cytoreductive 
surgery in advanced OC has been reported. However, OS rates are similar between the two 
treatment groups (38). The preliminary results of a large phase III trial (EORTC 55971) 
suggested that NACT followed by interval cytoreduction vs. primary cytoreduction were 
comparable in stages IIIC and IV disease and the OS rates were 30 and 29 months, 
respectively (56,57). In addition, patients assigned to neoadjuvant chemotherapy have no 
significant benefits related to survival, adverse effects, quality of life, or postoperative 
morbidity or mortality compared to primary cytoreductive surgery (57). The basis for the 
recommendation of the NACT followed by interval cytoreduction as an adequate routine 
therapy strategy for advanced OC has been challenged because current data are controversial 
and since this treatment strategy has no potential to improve PFS or OS. Hence, primary 
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optimal cytoreductive surgery remains the recommendation for the management of advanced 
OC (38,58). 
Despite improvement in surgical and chemotherapeutic strategies, the majority of women 
with advanced OC will experience disease recurrence and resistance to therapy. Hence, 
exploration of other treatment modalities, including targeted therapy, has been evaluated in 
multiple studies in recent years. Potential strategies for improving outcome and overcome 
resistance in OC include the inhibition of signal transduction pathways and targeting DNA 
repair. The most promising agents are the antiangiogenic agents, including monoclonal 
antibodies to VEGF ligand (bevacizumab), small molecule tyrosine kinase inhibitors (TKIs) 
targeting the VEGF pathway and soluble decoy VEGFR (aflibercept), in addition to 
monoclonal antibodies against epidermal growth factor receptor (EGFR) (59-61). The results 
of clinical testing of some of the targeted agents are mixed. Evaluation of the EGFR inhibitors 
revealed disappointing results, whereas the VEGF inhibitor bevacizumab showed promising 
results as single-agent in phase II trials in recurrent OC (59-61). Due to the positive results 
form these bevacizumab trials, GOG (GOG218), International Collaborative Ovarian 
Neoplasm (ICON7) and OCEANS began multiarm Phase III trials focusing on the application 
of bevacizumab in front-line therapy (61,62). GOG218 was a 3-arm placebo controlled study 
where the patients received carboplatin + paclitaxel + placebo (arm1) versus carboplatin + 
paclitaxel + bevacizumab followed by placebo (arm 2) versus carboplatin + paclitaxel + 
concurrent and extended bevacizumab (arm 3). The ICON7 was a 2-armed trial without 
placebo for OC patients at all stages (61,62). Preliminary data from the GOG218 trial 
demonstrated a significant improvement in the median PFS, 14.1 months versus 10.3 months 
in patients treated with concurrent and maintenance bevacizumab arm and the placebo arm, 
respectively. The median OS for the 3 arms was 39.3 months, 38.7 months and 39.7 months, 
respectively (61,62). Recent data for the ICON7 trial confirmed the findings of GOG218 in 
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term of PFS, but the data are immature regarding OS (61,62). OCEANS is a placebo-
controlled study comparing carboplatin and gemcitabine with or without bevacizumab in 
recurrent disease, and results are at present not available (62). Several potential targets in OC 
including folate receptor alpha (FRA), poly (ADP-ribose) polymerase (PARP), aurora kinase 
and mTOR are currently under evaluation (48). 
 
1.2.4 Clinicopathologic and molecular prognostic factors 
Despite increased knowledge regarding the etiology of OC, as well as the use of aggressive 
surgery and chemotherapy with newly developed drugs, there has been a minor change in the 
OS of OC patients. The prognosis of OC can be correlated with various clinicopathologic 
factors, including tumor stage, tumor grade, histological type, size of residual disease, age, the 
presence of ascites, and serum CA-125 levels (21,63-68). Tumor staging is an attempt to 
stratify patients into different prognostic groups based on the extent and volume of disease at 
diagnosis and it remains one of the most significant predictors of patient outcome. The FIGO 
classification (Table 1) is still the most commonly used staging guideline, and correlates well 
with patient outcome (21,27,37,65,66). 
 
A large number of molecular markers have been identified and suggested to be involved in the 
development and progression of OC, and serve as potential prognostic factors and therapeutic 
targets. These include proteins and genes implicated in cell proliferation, motility, 
angiogenesis, apoptosis, chemoresistance, and chromatin maintenance (68-72). DNA ploidy 
has been reported to be of independent prognostic value in OC (73-75). The EGFR family 
receptors, especially EGFR and HER2, are overexpressed in OC, and have been associated 
with advanced disease, chemoresistance and worse prognosis (61,76). Alterations in the tumor 
suppressor gene TP53 are the most frequent molecular events reported in OC (77), and the 
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relationship between mutations of TP53 and OC patient survival has been investigated in 
many studies. However, no obvious association with worse prognosis has been found 
(69,71,77). Numerous reports have investigated the possible roles of BRCA1 and BRCA2 
mutations with respect to prognosis and survival in OC, but results have been inconclusive. 
Some of these reports have shown a more favorable survival for OC patients who are carriers 
of BRCA1 and BRCA2 mutations compared to non-carriers, whereas other studies did not find 
a survival benefit for these patients (reviewed in 71). High serum Human Epididymis protein 
4 (HE4) level has been reported to be a strong and independent indicator of worse prognosis 
(78,79). Among the numerous other markers that have been suggested to a have prognostic 
value in OC are cancer-associated molecules of the integrin, matrix metalloproteinase (MMP) 
and Ets family (80), HBXAP (Rsf-1), NF-B, Fatty acid synthase, Apo-E, Mesothelin, 
Claudins, Kallikreins, Twist and Snail (68,72,81), cytokines, VEGF and cell cycle- and 
apoptosis-regulatory proteins (68), as well as the epigenetic modifications which involve 
DNA methylation, histone modifications and dysregulations of nucleosomes and miRNA 
(70). 
 
1.3. The serosal cavities 
1.3.1. Malignant effusions 
The embryonic coelomic cavity gives rise to the pleural, peritoneal and pericardial serous 
cavities. The term serous refers to the small amount of serum-like fluid each cavity contains. 
Under normal conditions the cavities are collapsed sacs invaginated by the lungs, heart or 
intestines. Each cavity is completely closed, except for the peritoneal cavity at the point at 
which it receives the fimbriated ends of the fallopian tubes. The outer layer of each serous 
cavity is the parietal layer, and the inner layer, which is directly in contact with the enveloped 
organ, is the visceral layer. The layers, which are separated by a thin film of fluid, are in 
 43 
contact with each other. Thus, under normal conditions, each cavity is only a potential cavity. 
Each cavity is lined by a monolayer of mesothelial cells beneath which is a layer of 
connective tissue, supplied with blood vessels, lymphatics and nerves (82-84). 
 
The appearance of a malignant effusion within the serosal cavities is a frequent clinical 
manifestation of advanced cancer and is a poor prognostic indicator (84). It usually affects the 
peritoneal or pleural space, with less frequent involvement of the pericardial space. The 
formation of malignant ascites is usually caused by ovarian, endometrial, breast, gastric, 
colorectal, lung, esophageal, pancreatic, hepatobilliary and primary peritoneal carcinomas 
(84-86). The development of malignant ascites may be influenced by factors such as 
lymphatic obstruction by tumor cells, immunomodulators, enhance vascular permeability, and 
increased production of fluid by cells lining the cavities (84,85,87). The most common 
symptoms reported by the majority of patients with malignant ascites are abdominal swelling, 
pain, nausea, anorexia, vomiting and fatigue (84,87,88). Treatment of malignant ascites is 
multidisciplinary. However, paracentesis and diuretics remain the mainstay of management of 
patients with malignant ascites, followed by several other modalities, such as peritoneovenous 
shunts, dietary measures, permanent drains, investigational therapies and IP chemotherapy 
(85,87,88). 
There are several etiologies for pleural effusions, with inflammatory/infectious causes and 
malignancy being the most common causes of exudative effusions (84,89-91). Lung and 
breast adenocarcinoma (AC) are the most frequent malignant diseases, followed by gastric 
AC, OC, malignant mesothelioma (MM) and lymphoma (84,89-91). Lymphatic obstruction, 
hematogenous spread, microvascular permeability, angiogenesis and chemotaxis have been 
suggested to contribute to tumor growth and the formation of malignant pleural effusions 
(91,92). The prognosis of patients with malignant pleural effusions is associated with various 
 44 
factors, including effusions volume (93), tumor type, and biochemical characteristics of the 
pleural fluid, such as pH and the concentration of protein and lactate dehydrogenase (LDH) 
(94). The median survival of patients with malignant pleural effusion after clinical diagnosis 
ranges between 4 to 8 months (93-95). Dyspnea is the first and commonest presenting 
symptom in patients with malignant pleural effusion (90). Other symptoms are cough, chest 
pain and heaviness (90). Several treatment strategies, including thoracocentesis, pleurodesis, 
fibrinolytics, pleurectomy, chemotherapy, pleuroperitoneal shunt and chest tube drainage, can 
be applied (90,96,97). 
 
While the biology of the different cancers affecting the serosal cavities and the clinical 
significance of effusions may differ, the presence of carcinoma cells in a peritoneal and/or 
pleural effusion indicates advanced stage disease and metastasis beyond the primary organ, 
and is associated with significant diagnostic and prognostic implications (84,86,90). The 
microenvironment in effusion specimens is unique and different from their corresponding 
primary tumor and other organs (84,86,98,99). Primary tumors are composed of two 
interactive compartments, parenchyma and stroma, in which tumor cells constitute the 
parenchyma, whereas the stroma is the surrounding connective tissue composed of various 
elements, including vasculature, fibroblasts, inflammatory cells and extracellular matrix (99-
101). Recent evidence indicates that the stroma is important for tumor maintenance, growth, 
invasion and metastasis (99-101). In contrast, mesothelial cells and leukocytes, and in the case 
of cancer, malignant cells, are the main constituents in the microenvironment of malignant 
effusions, with the absence of stroma and vasculature, resulting in a hypoxic 
microenvironment with reduced nutrient and oxygen supply. These floating cancer cells have 
a unique ability to proliferate and to progress despite the unfavorable environment and the 
lack of solid-phase scaffolding seen in primary tumors. The ability of malignant cells in 
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effusion to proliferate and survive may suggest their skill of acquiring nutrients, growth 
factors and other proteins produced by mesothelial cells and inflammatory cells or cancer 
cells themselves, contributing to disease progression through their unique phenotype (84,86).    
 
The cytological diagnosis between cancer cells, inflammatory cells (notably macrophages) 
and reactive or malignant mesothelial cells can at times be complicated. The morphological 
changes of reactive mesothelial (RM) cells caused by various stimuli such as injuries, 
chemotherapy or radiation, may give rise to severe cytoplasmic and nuclear alterations, 
resembling malignant cells (82,84,102). Furthermore, macrophages constitute a significant 
cell population in effusion specimens, resulting in possible confusion with cancer cells (103). 
Metastatic AC may be difficult to differentiate from MM. Thus, different methods such as 
immunohistochemistry (IHC), electron microscopy, FCM, polymerase chain reaction (PCR), 
immunofluorescence, telomerase activity, fluorescence in situ hybridization (FISH) and DNA 
ploidy analysis have been applied as adjuncts to morphology with the aim of increasing the 
diagnostic accuracy (84,86). IHC on cytospin specimens, formalin-fixed cell block sections, 
smears and liquid-based samples is the most widely used ancillary method in this setting, and 
has benefited from continuous improvement and expansion of the antibody panels available 
(84,85,104-106). Difficulties are commonly encountered due to the overlapping 
morphological characteristics of AC and MM or RM cell populations (86,106). The 
evaluation of the performance of various antibodies in differentiating between these entities is 
made complicated due to the fact that most of the reports have analyzed AC of different 
origins. IHC markers proposed to be valuable in differentiating between AC and MM are 
summarized in Table 2 (84,102,104,106-119).  
Recently, high-throughput molecular methods, including microarrays, proteomics, and 
comparative genomic hybridization (CGH) have been applied in this context (84,106).  
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Effusion specimens are suitable for FCM analysis, since they consist of single cells or small 
cell clusters. In effusion cytology, several investigators have applied FCM to simultaneous 
measure DNA aneuploidy (120-125) and expression of surface makers (124,125) to detect 
malignant cells, sometimes in combination with immunophenotyping of admixed lymphoid 
cells (126,127). The basis for biological studies is a reliable characterization of the cells in 
effusions. Our group has previously studied the potential of FCM immunophenotyping of 
epithelial and mesothelial cells in effusions in the diagnostic setting, and have subsequently 
applied FCM to investigate the expression of cancer-associated molecules in effusion 
cytology (84). However, the potential of FCM as a tool for the analysis of biological 
parameters (e.g., cell proliferation, cell signaling and apoptosis) in clinical specimens is still 
unfulfilled. The use of FCM in this setting requires further improvement in parameters such 
as instrument settings, panel selection and specimen handling.  
Table 2. Summary of proposed IHC markers in effusion diagnosis  
(84,102,104,106-119) 
Markers Target Cell Sensitivity (%) Specificity (%) 
Ber-EP4 
B72.3 
Leu-M1 (CD15) 
MOC-31 
BG-8 
CEA 
MUC4 
CA19-9 
Claudin-3 
TTF-1 
CA125 
Tenascin-X 
Calretinin 
Podoplanin (D2-40) 
CK5/6 
Thrombomodulin 
HMBE-1 
WT1 
Mesothelin 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
MM 
MM 
MM 
MM 
MM 
MM 
MM 
MM 
64-100 
35-98 
30-100 
67-100 
73-100 
0-100* 
96 
27-86 
86 
58-100 
95-100 
92 
58-100 
85-100 
53-100 
33-100 
84-98 
43-100 
75-100 
 
60-100 
42-100 
51-100 
76-100 
91-100 
41-98 
98 
97-100 
96 
39-100 
12-34 
89 
62-100
 
42-100 
57-89 
33-92 
0-80 
0-100 
61-100 
 
* Using both polyclonoal and monoclonal antibodies 
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1.3.2. Molecular alterations in malignant effusions 
Our group has reported on the differential expression of a large number of cancer-associated 
molecules in cancer cells in effusions compared to primary tumors and solid metastases. 
These molecules have biological functions related to tumor development, progression and 
disease outcome, and include tight junction proteins (claudins), cell adhesion proteins 
(cadherins and integrins), growth factors and their receptors (neurotrophin receptors, VEGF, 
and granulin-epithelin precursor; GEP), proteolytic enzymes (MMP) and microRNAs 
(miRNAs). Additionally, a large number of molecules have been found to be associated with 
OS and PFS in effusions, including the insulin-like growth factor (IGF) pathway, cytokines 
and chemokine receptors, signaling molecules (mitogen-activated protein kinases; MAPK, 
phosphatidylinositol-3-kinase pathway; PI3K), mitotic regulators (cyclins) and transcription 
factors (ETS family members, E-cadherin repressors) (72,84). These studies emphasize the 
need to study effusion specimens for their biological and clinical relevance. 
 
1.4. Apoptosis   
1.4.1 The apoptotic signaling networks 
Apoptosis or programmed cell death is a highly regulated process of cell deletion and plays an 
important role in the development and maintenance of cellular homeostasis. This process is 
characterized by typical morphological characteristics including cell membrane blebbing, cell 
shrinkage, chromatin condensation and nuclear fragmentation, finally ending with the 
engulfment by macrophages, dendritic cells or neighboring cells, thereby avoiding an 
inflammatory response in the surrounding tissue. Apoptosis is well balanced and regulated in 
a physiological context, and failure of this mechanism may result in pathological conditions 
such as developmental defects, autoimmune diseases, neurodegeneration or cancer (128-132). 
The characteristic morphological features that define apoptosis are mediated by caspase 
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activation and cleavage of specific cellular proteins within a cell (128,132). The apoptotic 
signaling pathways are divided in two major categories, namely the extrinsic, or death 
receptor-mediated, and the intrinsic, mitochondria-mediated pathways (Figure 14). In 
addition, other pathways also exist, such as the granzyme B-mediated and the endoplasmic 
reticulum (ER)-mediated pathways.  
The extrinsic pathway requires active participation of members of the tumor necrosis factor 
(TNF) superfamily of receptors (see below) and their ligands. Receptor-mediated apoptotic 
signaling is initiated by ligation of transmembrane death receptors to activate membrane-
proximal (activator) caspase-8 and -10, which in turn cleave and activate executor caspases 
such as caspase-3 and -7 or Bcl-2 family proteins, depending on the cell type (130-136).  
The intrinsic pathway is initiated by a number of factors, including DNA damage, hypoxia, 
survival factor deprivation, radiation, chemotherapy and kinase inhibitors. Upon disruption of 
the outer mitochondrial membrane, a set of mitochondrial proteins, including cytochrome c, 
second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI 
(Smac/DIABLO), Omi/HtrA2, apoptosis inducing factors (AIF) and endonuclease G, is 
released into the cytoplasm. Once in the cytosol, these apoptogenic proteins mediate the 
execution of cell death by promoting caspase activation or by acting as caspase-independent 
death effectors. The release of cytochrome c forms a complex with the adaptor protein Apaf-1 
and pro-caspase-9, resulting in activation of pro-caspase-9. The binding of pro-caspase-9 to 
the apoptosome forms the caspase-9 holoenzyme that cleaves and activates the downstream 
caspases, such as caspase-3, resulting in substrate cleavage and the appearance of apoptosis-
related morphological changes (Figure 14). Despite the difference in the initiation of both the 
extrinsic and intrinsic pathways, crosstalk between the two pathways at both the executioner 
and initiation levels has been reported (129,132-138).  
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In addition, cellular Ca
2+
 overload or perturbations of intercellular compartmentalization 
(139), DNA damage (140), and the lysosomes (141) have been shown to participate in 
apoptotic signaling.  
 
 
 
Figure 14. Scheme of extrinsic and intrinsic apoptotic pathways. 
 
1.4.2. Regulation of apoptosis 
The apoptotic machinery, both extrinsic and intrinsic, is regulated by several molecules, such 
as Bcl-2 proteins, p53, RAS, Smac/DIABLO, c-FLIP, NF-B, inhibitor of apoptosis proteins 
(IAPs), heat shock proteins (HSPs), protein kinases and the PI3K pathway members 
(132,133,136,142). The Bcl-2 family of proteins are the most important regulators of the 
intrinsic pathway, including both pro-apoptotic members such as Bax, Bak, Bok, Bad, Bmf, 
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Bcl-Xs, Bid, Bik, Bim, Noxa, Puma and Hrk, which promote the release of mitochondrial 
cytochrome c, and antiapoptotic members such as Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and Mcl-1, 
which act as repressors of apoptosis by blocking the release of mitochondrial cytochrome c 
(133,142,143). Regulation of the caspase cascade requires involvement of IAPs, which upon 
binding with caspases cause a steric block, resulting in inhibition of caspase-substrate binding 
(135,144,145).  
 
1.4.3. Dysregulation of apoptosis in cancer 
It is now evident that defects in the apoptotic pathways contribute to tumor initiation, 
progression, metastasis, and treatment failure (132,133,136,146,147). Among the various 
mechanisms for resistance to apoptosis is the inactivation of pro-apoptotic genes or 
overexpression of anti-apoptotic genes. Overexpression of Bcl-2 in follicular B-cell 
lymphoma, caused by the chromosomal translocation t(14:18), has been shown to cooperate 
with the oncoprotein c-MYC in suppressing apoptosis, thereby contributing to tumorigenesis 
in lymphomas and various cancers, and is associated with severity of malignancy and 
resistance to different chemotherapy drugs and radiation (147,148).  
Hypoxia is a frequent phenomenon in various solid tumors and the key regulator of hypoxia- 
induced apoptosis is hypoxia-inducible factors (HIFs), which combined with other factors can 
either induce or inhibit apoptosis (149,150). A large number of studies have shown that loss-
of-function of different tumor suppressor genes or oncogene gain-of-function contributes to 
increased levels of HIFs (HIF-1 and HIF-2 ), leading to tumor aggressiveness, metastasis 
promotion and patient mortality. These observations reveal the consequence of deregulation 
of apoptosis in tumor progression (149-153). 
 A large number of genes and molecules reported to be involved in the either induction or 
inhibition of apoptosis, including miRNAs, p53, the PI3K pathway, Apaf-1, IAPs, cFLIP, 
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Bcl-2 and Bcl-XL, have been reported to be aberrantly regulated or overexpressed in OC, 
resulting in chemoresistance (reviewed in 154-157). 
 
1.5. Death receptors 
1.5.1. The death receptor family 
Death receptors (DR) belong to the tumor necrosis factor receptor superfamily (TNFR) and 
consist of TNFR1, Fas/CD95, DR3, the TNF-related apoptosis-inducing ligands (TRAIL) 
receptors DR4 (TRAILR1) and DR5 (TRAILR2), DR6, ectodysplasin A receptor (EDAR) 
and the low-affinity nerve growth factor receptor p75
NGFR
. These receptors contain a 
cytoplasmic region of approximately 80 amino acids termed the death domain (DD). Once 
DR are activated by corresponding ligands, the DD recruits a number of molecules that 
mediate both death and proliferation of the cells. These molecules in turn recruit other 
molecules via their DD, followed by activation of caspases resulting in destruction of the cell. 
Decoy receptors counting TRAILR3 (DcR1), TRAILR4 (DcR2), DcR3 and osteoprotegrin 
(OPG) do not possess DD and hence are not able to transmit apoptotic signals upon binding to 
death ligands (146,158,159).  
 
1.5.2. Death receptor signaling 
Two types of DR signaling complexes have been described. The death-inducing signaling 
complex (DISC) induced by TNFR1 is different from the DISC induced by CD95 or DR4 and 
DR5. The DISC complexes induced by CD95, DR4 and DR5 consist of oligomerized/ 
trimerized receptors, the DD (Death Domain)-containing adaptor protein FADD (Fas-
Associated Death Domain), procaspase-8, procaspase-10 and the cellular FLICE-inhibitory 
protein (FLIPL/S). Activation of procaspase-8/10 at the DISC by cleavage leads to the 
 52 
activation of downstream effector caspases (caspase-3,-6 and 7) and apoptosis. Two different 
pathways can be activated depending on the DR and cell type (158-160).  
Stimulation of TNFR1 results in the formation of two complexes. Complex I is assembled at 
the membrane and includes TNFR1, TNF, RIP (receptor-interacting protein), TRADD 
(TNFR-associated death domain protein) and TRAF-1/2 (TNFR-associated factor), which is 
responsible for activating the NF-B signaling pathway. Due to the lack of FADD and 
procaspase 8, complex I is dissociated from TNFR1 and translocated to the cytosol in order to 
bind FADD and recruit caspase 8/10 forming complex II that activates downstream death 
signaling. Upon successful activation of NF-B by complex I, the cellular level of FLIPL 
increases, resulting in blockage of apoptosis and promoting of cell survival (158-160) (Figure 
15).  
Upon ligand binding, DRs preferentially induce apoptosis in cancer cells. However, tumor 
cells can flee DR-induced apoptosis through several mechanisms, such as overexpression of 
decoy receptors, alterations of antiapoptotic or prosurvival molecules, dysfunctional DISC 
components, mutation of the receptors, increased expression of IAP proteins and increased 
expression of antiapoptotic miRNAs (159,161,162). 
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Figure 15.  Two types of DR signaling complexes.  
 
1.5.3. Non-apoptotic DR signaling  
Several studies have demonstrated that DR and their ligands are not implicated only in 
promoting cell death but also in promoting cell survival and proliferation (163-166), pro-
inflammatory activity (167-169) and tumor growth and progression (169-172). These non-
apoptotic signaling activities are mediated by NF-B, the MAPK member ERK, and AKT 
(163-172) (Figure 15).                    
 
1.5.4. Resistance of OC cells to DR-mediated apoptosis                                                                             
The current treatment regimen (cisplatin or carboplatin coupled with paclitaxel) of OC 
renders cancer cells to undergo apoptosis. However, the biggest hurdle in the treatment of OC 
is resistance against currently applied drugs observed in patients. Although the underlying 
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mechanisms of this resistance are not fully clear, growing evidence suggest deregulation of or 
defects in apoptotic pathways, as well as activation of survival pathways (155,162,173). A 
number of studies have demonstrated variable sensitivity to TRAIL-induced apoptosis in OC 
cell lines (174-179). In addition to lack of or reduced DR expression (177, 180,181), cFLIP 
and XIAP levels have been implicated in chemoresistance as well (176-179). Increased 
turnover of caspase-3 may be the underlying cause of inducible TRAIL resistance in 
previously sensitive OC cells (182), and activation of PI3K by malignant ascites fluid 
conferring TRAIL resistance by increased cFLIP level was documented (183). Alternatively, 
IL-8 was shown to inhibit TRAIL-induced apoptosis via the p38-MAPK pathway (184). 
CD95-induced apoptosis in a wild-type p53 OC cell line was inhibited by increased cFLIP 
expression, thus preventing procaspase-8 recruitment and activation at the DISC level (185). 
Despite the expression of both Fas and sFas, primary OC cultures are resistant to Fas-
mediated apoptosis (186). 
 
Previous studies of OC cell lines focused on the enhancement of TRAIL-mediated apoptosis 
by chemotherapeutic drugs (175,181,187-190). Results from these studies demonstrated that 
sensitivity to TRAIL-induced apoptosis was enhanced in combination with chemotherapeutic 
agents in OC cell lines with variable sensitivity to TRAIL-induced cytotoxicity. Possible 
mechanisms for this potent apoptotic outcome of combined TRAIL-therapeutic drugs are 
related to increased caspase activation (175,189), upregulation of TRAIL receptors (187,190), 
induced expression of pro-apoptotic proteins and downregulation of anti-apoptotic proteins 
(190).  
 
As a supplement to the therapeutic potential of TRAIL-based therapy in OC, substantial 
research has focused on the prognostic implications of DR expression and TRAIL sensitivity. 
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DRs and their ligands have been shown to be differently expressed in OC and interpretation 
of their clinical role is controversial (180,191-194). Horak et al. reported that neither DR4 and 
DR5 nor TRAIL expression levels were significant predictors of survival (180), whereas 
Duiker et al. and Lancaster et al. found that high expression of TRAIL was associated with 
better patient survival (191,193), with no such role for DR4 and DR5 (191). Yet another 
investigator has shown that high expression of DR5 was associated with a poor prognosis in 
patients with invasive tumors and patients with grade 3 tumors of the serous type (192). 
Furthermore, the combined expression of 2 proteins (TRAIL and DR5, DcR2 and Cyc, FLIP 
and DR5, FLIP and DcR2, DcR1 and DR5 or DR4 and FLIP) was associated with prognosis 
(192).  
Frequent Fas expression in OC was shown in a number of studies (186,191,195,196). In 
contrast, in other studies widespread expression of Fas was detected in benign ovarian 
samples, but was almost absent in carcinoma cases (197). Positive Fas expression was 
associated with better progression-free and disease-specific survival in one study (191), while 
another study found that FasL expression in carcinoma specimens was associated with a less 
favorable prognosis than FasL-negative cases (196). Additionally, OC patients with a serum 
soluble Fas levels lower than 1.5 ng/ml had significantly higher survival rate than patients 
with levels above 1.5 ng/ml (198).        
TNF-R1 and TNF-R2 expression has been studied in both benign and malignant ovarian cells 
by several investigators (199-201). TNF-R1 expression was detected in both benign and 
malignant lesions (199-201). The expression of TNF-R2 was reported in 51% of malignant 
specimens (199), but was almost absent in benign lesions (199,201). In contrast, TNF-R2 was 
reported to be absent in carcinoma cells (200,201), but confined to infiltrating inflammatory 
cells (200). Analysis of the association between TNF-R1 and TNF-R2 expression and patient 
outcome showed that patients with TNF-R2-positive tumors had poor survival (199). 
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Ascites obtained from women with advanced OC has been demonstrated to inhibit death 
receptor-induced apoptosis through v5 integrin-mediated focal adhesion kinase and Akt 
activation (183,202). This observation suggests that ascites actively contributes to the 
progression of OC cells in effusion and that the effusion microenvironment may play an 
important role in regulating the resistance of OC cells to DR-mediated apoptosis. Further 
support of the notion that DRs are involved in OC progression is the demonstration that 
autocrine production of TNF- by OC cells generates a constitutive network of other 
cytokines, angiogenic factors, and chemokines that may act in an autocrine and paracrine 
manner to promote tumor progression and development (203,204). 
 
1.6. Caspases  
1.6.1. Apoptotic function of caspases 
Apoptosis, an evolutionarily conserved type of cell death, requires a specialized cellular 
mechanism. The main component in this pathway is a family of proteases called caspases. 
The study of caspases originated from the discovery that the C. elegans ced-3 gene, whose 
protein product is necessary for cell death in Caenorhabditis elegans, encodes a homologue of 
the IL-1 converting enzyme (ICE) (205). This protein was able to induce apoptosis when 
overexpressed in mammalian cells (205). At present, about 14 mammalian caspases have been 
characterized and they share a number of similar features, including amino acid sequence, 
structure, and substrate specificity (129,206). Caspases are synthesized as inactive 
proenzymes containing three domains: NH2-terminal domain, followed by a large p20 and a 
small p10 subunit. These proenzymes can be cleaved to form active enzymes resulting in 
induction of apoptosis. All caspases, except for the serine protease granzyme B, can cleave 
substrates at the Asp-Xxx bond, a unique feature among mammalian proteases (129,207). 
Caspases contain catalytic triad residues, consisting of the active site Cys285, His237 and the 
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backbone carbonyl of residue 177 (129,208). They are classified into three groups based on 
their function: 1) Inflammatory caspases, including caspase-1, -4, -5, -11, -12, -13 and -14, 
which are involved in inflammatory processes rather than apoptosis. 2) Apoptotic initiator 
caspases, which possess long prodomains containing either a death effector domain (DED) 
(caspase-8 and -10) or caspase activation and recruitment domain (CARD) (caspase-2 and -9). 
These caspases interact with upstream adaptor molecules. 3) Apoptotic effector caspases, 
comprising caspase-3, -6, and -7, are identified by the presence of a short prodomain and they 
are processed and activated by upstream caspases, resulting in downstream execution of 
apoptosis by cleaving multiple cellular substrates (129,208-210). The list of proteins that are 
cleaved by caspases during apoptosis and/or inflammation is growing. These substrates 
include structural proteins, regulators of transcription/translation, kinases and signaling 
intermediaries (210,211). 
 
1.6.2. Non-apoptotic role of caspases 
Growing evidences for caspase activation and identification of caspase substrates in absence 
of apoptosis suggested a role for caspases in controlling cell proliferation, differentiation and 
immune functions (135,212). Proteolysis exerted by the catalytic domains and non-proteolytic 
function exerted by the prodomains has been indicated to be involved in the non-apoptotic 
functions of caspases. Furthermore, caspases may become activated independently of or 
without inducing the apoptotic cascade, resulting in cleavage of specific subset of substrates 
such as cytokines, kinases, transcription factors and polymerases to avoid cell demolition 
(135,212). c-FLIP, human caspase-12 and CARD-only proteins may be involved in the 
regulation of the non-proteolytic functions of caspases. High concentration of c-FLIPL at the 
level of the DISC prevents recruitment of caspase-8 to the DISC resulting in impeded 
caspase-8 activation that blocks cell death. Instead, c-FLIPL-mediated NF-B activation is 
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promoted (135,212,213). Interestingly, in addition to participation in cell death, caspase-8 and 
caspase-3 have also been reported to be involved in non-apoptotic functions such as 
embryonic development, T and B cell proliferation, macrophage differentiation and 
remodeling of cellular populations in response to cerebral ischemia (213-215).  
 
1.7. c-FLIP 
1.7.1. The role of c-FLIP in regulation of DR-mediated apoptosis 
Apoptosis mediated by DRs is regulated by inhibitor proteins, including c-FLIP. To date, 
several c-FLIP splicing variants have been identified at the mRNA level. However, at the 
protein level only two splice variants, the long isoform c-FLIPL(55kDa) and the short isoform 
c-FLIPs(26 kDa), were shown to demonstrate different molecular mechanisms for inhibiting 
the activation of pro-caspase-8 (216-218). cFLIPL is structurally similar to pro-caspase-8, 
containing two death effector domains (DED) at the N-terminus and caspase-like domain at 
the C-terminus. However, this domain lacks the catalytic cysteine residues which are essential 
for the catalytic activity of caspase-8, and hence, it is catalytically inactive. The short isoform 
c-FLIPs is structurally similar to viral FLICE-inhibitory proteins (v-FLIP) (219). Structural 
variations in all forms of c-FLIP reflect different functional roles, pointing to modulation of 
caspase-8/10 activity in the physiologic regulation of normal tissue development and in 
pathological conditions. All isoforms of c-FLIP, when expressed at high level, have been 
described to bind to FADD/TRADD using their DED motif and compete with pro-caspase-
8/10 for the recruitment at the DISC, resulting in prevention of the pro-caspase proteolytic 
cleavage and activation. This may be the common mechanism to inhibit the transduction of 
apoptotic signaling and promotion of cell survival (216-219) (Figure 15). Despite the role of 
cFLIPL as an inhibitor of caspase-8 activation, other studies have demonstrated that cFLIPL is 
also able to trigger caspase-8 activation. This double function has been found to depend on 
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various parameters, including the cellular context and the caspase-8 to cFLIPL ratio (212,220-
222).  
Elevated expression of c-FLIP has been described in a variety of human tumors, including 
melanoma (216, 223), colorectal carcinoma (224,225), pancreatic carcinoma (226, 227), non-
Hodgkin lymphomas (228,229), breast carcinoma (230) and OC (176-180,185,231-233). 
Recent findings indicate that c-FLIP expression plays a key role in conferring cellular 
resistance to death-receptor mediated apoptosis. Several studies have described that 
downregulation of c-FLIP expression results in sensitizing various types of resistant cancer 
cells to Fas and TRAIL-induced apoptosis (177-180,183,226,227,230-234).  
 
1.7.2. The clinical role of c-FLIP in OC 
Published data regarding the clinical role of c-FLIP overexpression in human cancers has only 
recently begun to accumulate (225,235-238). c-FLIP expression in OC has been analyzed in 
only few studies and results are inconclusive with respect to its clinical role. Two studies by 
Horak et al. and Duiker et al. (180,191) demonstrated no association between c-FLIP 
expression and survival in analysis of primary OC, while Bagnoli et al. (239) reported that 
combined expression of p53 and c-FLIP expression was associated with unfavorable 
prognosis compared to lack of both with respect to both PFS and OS in primary OC. In 
multivariate analysis in which the prognostic role of p53 and c-FLIP was separately analyzed, 
the latter protein was an independent prognostic marker (239).  
 
1.8. Phosphatidylserine  
1.8.1. Phosphatidylserine (PS) in mammalian cells 
Mammalian cell membranes contain several types of phospholipids which are unevenly 
distributed between the two leaflets of the plasma membrane. The negatively charged PS 
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constitutes approximately 2-10 % of the total cellular lipid. In addition to a structural 
function, the preservation of PS in the cytosolic leaflet of cells has an important role in cell 
physiology, as it facilitates binding of proteins at the inner membrane surface, serves as a 
cofactor for several membrane-bound enzymes (e.g., protein kinase C), participates in 
signaling pathways and promotes membrane-fusion during exocytosis and similar processes 
(240-244).  
 
1.8.2. Cell surface exposure of PS 
PS is normally localized at the cytoplasmic side of the plasma membrane. However, certain 
conditions may lead to exposure of PS on the outer leaflet of the plasma membrane, where it 
can initiate and participate in several important biological processes, such as blood 
coagulation, cell clearance, immune regulation and apoptosis (240-244). PS cell surface 
exposure has been shown in erythrocytes, activated platelets and erythroid precursors 
(241,245), in undifferentiated tumor cells (246,247) and in apoptotic lymphocytes (248), as 
well as in cancer cell lines derived from different cancer types such as malignant melanoma, 
prostate carcinoma, renal carcinoma, glioblastoma and rhabdomyosarcoma (249). Riedl et al. 
further demonstrated that PS externalization was significantly higher in these cancer cell lines 
compared to the corresponding non-tumorigenic control cells, and association between the 
levels of PS exposure and malignancy was observed in four malignant melanoma cell lines 
compared to melanocytes (249). Thus, PS exposure was suggested as potential marker to 
differentiate between malignant and non-malignant cells, as well as an informative biomarker 
for diagnosing disease and a target for cancer therapy (249,250). The externalization of PS in 
activated platelets serves as a procoagulant surface; in erythroid cells it plays an important 
role in cell maturation, whereas in erythrocytes and undifferentiated tumor cells, PS exposure 
mediates cell recognition and phagocytosis by macrophages and other cells (241, 245-248). 
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Furthermore, numerous reports have shown elevated expression of PS on the outer leaflet of 
the plasma membrane of different cell types undergoing apoptosis, including lymphocytes, 
thymocytes, tumor cell lines of lymphoid and neural origin, smooth muscle cells and vascular 
endothelial cells (248,251-254).  
 
1.8.3. The PS-binding protein annexin V 
To date, several PS-binding compounds, including proteins, peptides and small chemical 
entities have been described (250). Peptides and small chemical entities have low affinity for 
binding PS, whereas proteins demonstrate higher affinity for binding it (250). Annexins 
represent a large family of closely-related calcium-binding membrane proteins that are widely 
expressed in eukaryotes (255). Annexin V, a 35-kDa Ca
2+
-binding protein, was first described 
by Reutelingsperger et al. as a vasculature-derived protein with strong anticoagulant 
properties that binds with high affinity to PS (256). The affinity (257,258) and specificity 
(259) of this binding has been previously reported. Annexin V has been intensively 
investigated as a molecular imaging agent to visualize PS-expressing apoptotic cells in vitro 
and in vivo (260,261). Fluorochrome-conjugated Annexin V in combination with a membrane 
impermeable DNA dye such as propidium iodide (PI) or 7-amino-actinomycin-D (7-AAD), 
has been used to differentiate between viable, apoptotic and secondary necrotic cells 
(252,253, 262-265).  
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2. AIMS OF THE STUDY 
Despite the established role of FCM in the diagnosis of hematological neoplasms, the use of 
this technique in diagnosis and clinical research of non-hematological cancers in general and 
effusion cytology in particular still requires improvement in way of optimization and 
calibration. In addition, quantitative analysis of molecules involved in apoptosis and drug 
resistance may represent an important tool for evaluating treatment response and prognosis in 
advanced and/or recurrent OC.  
 
The aims of the study were therefore: 
 
1. To improve the ability of FCM to detect epithelial cells in effusion by focusing on issues 
such as instrument settings, panel selection and specimen handling/storage.  
 
2. To quantify apoptosis and to study the relationship between molecular markers of 
proliferation, survival and apoptosis in OC effusion specimens.  
 
3. To study the association between proteins which mediate apoptosis or cell survival and 
clinicopathologic parameters, including chemotherapy response and survival in OC.  
 
4. To compare the expression patterns of the above molecules in OC, breast carcinoma and 
MM effusions.  
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3. MATERIALS AND METHODS 
3.1. Cell lines 
Nine different cell lines, detailed in Table 3, were used in the present thesis as control cells. 
All cell lines were in-house lines originally purchased from ATCC, with the exception of 
OVCAR-8 cells, which were a gift from Professor Reuven Reich at the Hebrew University, 
Jerusalem, Israel.  
 
3.1.1. Preparation of cell lines 
All cell lines were propagated in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with fetal bovine serum to a final concentration of 10%. Depending on the 
analysis, cells were both harvested by scraping or trypsination and analyzed fresh or after 
freezing in -70°C in RPMI 1640 medium supplemented with 50% FBS and 20% 
dimethylsulfoxide (DMSO). 
 
Table 3. Cell lines used in the thesis 
Cell lines Origin 
MDA-MB-231 Breast adenocarcinoma 
SK-BR-3 Breast adenocarcinoma 
T47-D Breast adenocarcinoma 
OVCAR-8 Ovarian adenocarcinoma 
SKOV-3 Ovarian adenocarcinoma 
OVCAR-3 Ovarian adenocarcinoma 
NCI-H520 Squamous cell carcinoma of the lung 
HS-Sultan Burkitt lymphoma cells 
MSTO 211H Mesothelioma 
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3.2. Peripheral blood leukocytes (PBL) 
Peripheral blood leukocytes (PBL) from healthy donors were additionally analyzed. Briefly,  
after centrifugation in lymphoprep (AXIS-SHIELD, Oslo, Norway), mononuclear cells were 
separated from at the sample/medium interface and the harvest fraction was washed twice by 
addition of 15 ml 0.9% NaCl and by centrifugation at 1000 rpm for 10 minutes. The pellet 
was suspended in RPMI 1640 medium with 50% FBS. Cells were counted and divided 
equally into each cryo-tube (Greiner bio-one). Prior to freezing, an equal volume of 20% 
DMSO was added and the cells were frozen at -70° C.  
 
3.3. Clinical material  
The studied specimens in this project consisted of malignant (OC, MM and breast carcinoma) 
and reactive fresh non-fixed peritoneal and pleural effusions submitted for routine diagnostic 
purposes to the Department of Pathology, Norwegian Radium Hospital, Oslo University 
Hospital, during 1999-2007. The material included a limited number of primary peritoneal 
serous carcinoma and tubal serous carcinoma specimens. As these have closely-linked 
histogenesis and phenotype to that of their ovarian counterparts, all are referred to as OC in 
paper II, IV and in this thesis.  
 
In paper I, antigenic immunoreactivity of fresh and frozen specimens was analyzed in 10 fresh 
non-fixed effusions consisting of 8 AC, 1 MM and 1 one reactive specimen. In addition, 20 
effusion specimens were compared using both FCM and ICC.  
The material studied using FCM in paper II consisted of 95 OC effusions (80 peritoneal and 
15 pleural). These were obtained from 77 patients treated at the Section for Gynecologic 
Oncology, Division of Obstetrics and Gynecology, Norwegian Radium Hospital, Oslo 
University Hospital, of whom 12 had more than 1 effusion. Additionally, suspensions from 20 
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non-matched primary carcinomas were analyzed following a request by one of the Reviewers 
to study primary carcinomas from patients who did not have effusions at diagnosis.  
In paper III, 12 OC effusions were tested.  
Of the 95 OC effusions in paper II, 76 specimens, consisting of 63 peritoneal and 13 pleural 
effusions, were analyzed for annexin V expression in paper IV.  
The material studied in paper V consisted of 27 cytological specimens, including 22 effusions 
and 5 fine needle aspirates. Twenty specimens were malignant, including tumors of different 
origin, and 7 were reactive. 
In paper VI, a total of 69 effusions, including 61 peritoneal and 8 pleural, were studied for c-
FLIP expression. However, only a limited number of these effusions (21 to 28) were analyzed 
for DR and cFLIP expression in papers II and V, respectively.   
 
3.3.1. Preparation of effusion samples 
In order to avoid any bias that may be caused by different handling, and to secure minimal 
cell death, effusions were processed immediately after tapping with centrifugation for 10 
minutes at 2000 rpm. From the resulting pellet, two Diff-Quik
®
-stained and two 
Papanicolaou-stained smears were prepared and evaluated for adequacy by an experienced 
cytopathologist (Prof. Ben Davidson). The specimens were considered adequate when a 
distinct tumor cell population was observed and cell degeneration was absent. Based on 
specimen volume and the number of cancer cells, the remaining material was divided for 
freezing in -70°C in RPMI 1640 medium with 50% FBS and 20% DMSO at ratio 1:1 and for 
cell block preparation using the thrombin clot method (82). Cell blocks were fixed in 4% 
buffered formalin overnight, as for surgical specimens, in order to avoid any methodological 
bias regarding sample handling in comparison of effusions with solid tumors. 
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3.3.2. Pathological diagnosis  
An experienced pathologist evaluated and diagnosed all specimens and new cancer diagnoses 
on either cytology or histology samples were confirmed by a second senior pathologist. All 
cases, including smears and hematoxylin and eosin-stained sections from all effusions and 
slides from solid tumors were reviewed by Prof. Davidson. 
 
3.3.3. Clinical data 
Relevant clinical data, including patient age, FIGO stage, residual disease volume, dates of 
chemotherapy administration and clinical response following each chemotherapy course, as 
well as PFS and OS data, were obtained from the Section for Gynecologic Oncology, 
Division of Obstetrics and Gynecology, Norwegian Radium Hospital, Oslo University 
Hospital. 
 
3.3.4. Ethics 
This project was approved by the Regional Committee for Medical Research Ethics Norway 
(S-04300). Norwegian pertinent laws and rules, including Biobank law and Data Inspectorate 
Regulations, were strictly followed. 
 
3.4. FCM immunophenotyping of cells in effusions 
FCM immunophenotyping is rapid, reproducible and sensitive, and is a reliable method for 
detecting cellular (cytoplasmic, nuclear and surface) antigens. Multi-color FCM provides the 
opportunity to evaluate multiple antigens simultaneously, making it possible to characterize 
various cell populations in a more precise manner (84). Cytological specimens such as 
effusions are suitable for FCM analysis, due to the presence of viable cells in suspension. In 
paper I, we optimized the conditions for FCM immunophenotyping of effusion specimens 
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applying four-color analysis. The results from paper I provided the basis for FCM analysis of 
DRs and Annexin V in paper II and IV, respectively, and FCM constitutes the main technique 
applied in this thesis. A panel of antibodies that allows for rapid and effective differentiation 
between cells of epithelial, mesothelial and hematological origin has been established (84) 
and the basis for reliable detection of cells in effusions has been shown in previous studies 
(116, 266). The Ber-EP4 antibody was most frequently and widely immunoreative in AC cells 
(267), and was thus used in the antibody panel in all papers in the present thesis, in 
combination with the leukocyte marker CD45, in order to guarantee that only AC cells were 
analyzed for target protein expression. In addition, an EpCAM antibody, directed against the 
same cell surface adhesion molecule as Ber-EP4, was used as control for the Ber-EP4 reaction 
in apoptotic cells in papers II, V and VI. EpCAM stains epithelial cells and some mesothelial 
cells and is overexpressed in a variety of carcinomas (268). Characterization of MM was 
performed applying an anti-EMA antibody instead of Ber-EP4.  
 
3.4.1. Control of instrument performance  
FCM was undertaken using the FACSCalibur flow cytometer (Becton-Dickinson, San Jose, 
CA) equipped with a 15 mW Argon-ion laser (488 nm) and 12 mW red diode laser (635 nm). 
FITC (FL1, BP 530/30 nm), PE (FL2, BP 585/42 nm), PerCP (FL3, LP 670 nm) and APC 
(FL4, BP 661/16) measurements were collected in the logarithmic mode. Control of 
instrument performance and time delay calibration were performed using FACSComp 
software version 4.1, Calibrite™  3 beads and Calibrite™ APC beads (all from BD 
Biosciences). 
3.4.2. Evaluation of FCM immunophenotyping 
Evaluation and scoring of FCM immunophenotyping was undertaken using CellQuest 
Software (BD Biosciences) in papers I and II, and FlowJo analysis software (Tree Star Inc., 
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Ashland, OR) in papers III-VI. The percentage of tumor cells expressing the relevant markers 
was scored. Expression in <1% of cells was scored as negative. 
 
3.5. Detection of apoptosis 
Several methods have been described for detection of cell death-related parameters, including 
membrane alterations, mitochondrial changes, caspase activity and DNA fragmentation (269-
273). Transmission electron microscopy (TEM), considered as the gold-standard test, has 
been used to identify the ultrastructural morphological changes in cells undergoing apoptosis 
(271-273). However, TEM has limitations as an apoptotic detection method, including high 
cost and being a time-consuming procedure, making screening of large specimens difficult. In 
addition, apoptotic cells detected by TEM are at the late state of apoptosis and often are 
deficient in the structures and antigens that would identify the cell type (271-273). For any 
given method, limitations regarding sensitivity (positive identification of apoptotic cells) and 
specificity (detection of apoptotic vs. necrotic cells) in detecting apoptotic cells need to be 
considered, and recognition of apoptosis is thus more reliable when more than one viability 
assay is performed (269,270,274). Apoptosis is an event of different induction and execution 
kinetics. Thus, detection of cells undergoing apoptosis generally relies on a specific marker 
that is expressed in variable time intervals. Awareness of the time-point in which specific 
markers are being detected is therefore important for the rational application of methodology 
(269,275). 
 
Multicolor FCM provides the opportunity to evaluate multiple antigens simultaneously, 
making it possible to characterize and quantify various apoptosis features in a more reliable 
way (262,263, 276,277). An assay for studying apoptosis in effusion specimens, detecting 
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cleaved caspase expression and DNA fragmentation by the TUNEL reaction, was established 
in paper III. This assay was then used in paper V. 
 
Alterations in lipid composition of the cell membrane have been reported as an early sign of 
apoptosis (251-253,269,273). PS exposure on the outer leaflet of the cell membrane can be 
detected by FCM using the fluorochrome-conjugated anticoagulant protein Annexin V 
(257,261,262). Although this method is quite sensitive, distinction between live, apoptotic, 
and late apoptotic/necrotic cells is not possible unless a plasma membrane permeability 
marker such as PI or 7-AAD is used in conjunction with Annexin V (261-263). Caution 
should be considered in interpretation of results from Annexin V assay after mechanical or 
enzymatic detachment of adherent cells from culture flasks, as these have been reported to 
increase exposure of PS, leading to experimental bias (262,278). 
 
A hallmark of apoptosis is the activation of caspases (207,208). Under normal physiological 
settings, caspases are constitutively present in the cytoplasm as zymogens with low intrinsic 
activity, which become activated upon cleavage. The expression of cleaved caspase-3 and -8 
were studied in papers III and V using specific antibodies that recognize epitopes exposed 
upon caspase cleavage. Other approaches were developed to detect intracellular caspase 
activation using fluorochrome-labeled inhibitors of caspases (FLICA) or specific fluorogenic 
caspase substrates (269,273). However, FLICA seems to bind additionally to targets other 
than activated caspases (279). 
DNA fragmentation cause by endonucleases in cells undergoing apoptosis generates a 
multitude of DNA double-strand breaks (DSB) (280,281) and can be detected by the TUNEL 
reaction assay (269,273). In this method, exogenous terminal deoxynucleotidyl transferase 
adds fluorochrome-labeled triphosphodeoxynucleotides such as dUTP to the 3’-hydroxyl ends 
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of double-strand DNA, which allows for detection by image cytometry or FCM (269,281). 
Significant DNA fragmentation is suggested to be a specific marker of apoptosis and the 
number of DSBs in apoptotic cells is usually much higher than in necrotic cells, ensuring their 
discrimination by using the TUNEL assay (282). However, it has been shown that TUNEL is 
not always able to distinguish between different forms of cell death (283,284). In addition, 
there are cases where apoptotic or apoptotic-like cell death proceeds without extensive DNA 
degradation, leading to inadequate identification of apoptotic cells by TUNEL (269,274). 
Alternatively, identification of DNA degradation by extracting the DNA can be performed 
using agarose gel electrophoresis. Multiple DNA fragments 180-200 bp in length resulting 
from apoptosis can be visualized as a DNA ladder (285,286). As to TUNEL, this assay is also 
not capable of detecting apoptosis in situations where apoptosis-induced DNA degradation 
occurs in the absence of internucleosomal DNA fragmentation (287,288). 
 
Several mechanisms have been described explaining mitochondrial function in apoptosis, 
including release of apoptogenic proteins into the cytosol upon mitochondrial outer 
membrane permeabilization (MOMP). The mitochondrial changes result in a release of 
cytochrome c and an array of cell death-modulating small proteins such as AIF, EndoG, 
Omi/HtrA2 and Smac/DIABLO, normally enclosed in the intermembrane space of the 
organelle (289). Mitochrondrial transmembrane potential loss, which is an early event in 
apoptotic cells, can be examined by cytometric assays using membrane-permeable lipophilic 
cationic fluorochromes such as rhodmaine 123, 3,3-dihexiloxa-dicarbocyanine (DiOC6(3)) or 
5,5', 6,6'-tetrachloro-1,1', 3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1) 
(269,271,290). The probes are taken up by live cells, accumulate in the mitochondria, and 
efflux into the cytosol of apoptotic cells, leading to changes in fluorescence intensity. There 
are emerging data suggesting that, depending on the model of apoptosis, the collapse of 
 71 
mitochondrial transmembrane potential may not be a universal requirement for apoptosis 
(291,292). 
 
3.6. Immunohistochemistry (IHC) 
The technique of IHC allows for the visualization of epitopes in situ in histological tissue 
sections or cytological smears. A series of innovations in the assays and reagents and the 
introduction of mechanization (293,294) have improved the ease and technical reliability of 
this technique leading to widespread application as a complement to morphology 
(104,109,295). IHC is an important tool to apply in the diagnosis of cancer of unknown origin 
or to determine the nature of the cells when their degree of malignancy is uncertain (294,295). 
However, it is now appreciated that IHC experiments may result in false-negative or false-
positive staining, owing to over-fixation or poor tissue fixation with formalin, poor handling 
of reagents, inadequate antigen retrieval and improper antibody dilution (293-295). 
 
In paper I, the performance of IHC in terms of sensitivity and specificity was compared to 
FCM. Briefly, formalin-fixed paraffin-embedded cell block sections, 4 micron-thick, were 
mounted onto silane-coated slides, air-dried at 60°C for 45 min and then at 37°C overnight. 
Slides were deparaffinized and rehydrated prior to staining. The antigen retrieval was 
performed by using a microwave oven. Staining was performed using the EnVision 
Peroxidase (DAB) kit (Dako). Appropriate positive and negative controls were used.  
Staining intensity and extent (percentage of stained cells) were scored. Staining intensity was 
scored semi-quantitatively as 0-3 corresponding to absent, weak, moderate and strong staining 
pattern. Staining extent was determined as the average number of cells in each X40 field 
throughout the specimen. 
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3.7. Western blotting (WB) 
WB has been reported to be a potent method for the immunodetection of the presence, relative 
abundance, relative molecular mass and post-translational modification of proteins, following 
electrophoresis. The value of this technique originates from its ability to provide simultaneous 
resolution of multiple immunogenic antigens within a sample for detection by specific 
antibodies (296). However, several conditions, including lysis, antibody concentrations, the 
quality and volume of protein loaded, membrane background fluorescence, membrane type 
and porosity, washes, incubation time and exposure, may influence the final results (296).  
 
In paper VI, WB was used to test two commercial c-FLIP antibodies in a panel of four cell 
lines, consisting of OC and MM. The best performing antibody was chosen for further study 
of effusion specimens applying FCM. In brief, cell pellets were lysed in ice-cold lysis buffer. 
Protein lysates (25g per lane) were separated by SDS polyacrylamide gel electrophoresis and 
blotted onto Immobilon-P membranes. Membranes were blocked overnight in 5% nonfat dry 
milk in Tris buffered saline-Tween. Filters were incubated with anti-c-FLIP antibodies in 5% 
milk in TBST. The secondary HRP-conjugated anti-rabbit IgG and HRP-conjugated anti-
mouse antibodies were applied. The enhanced luminol-based chemiluminescent plus WB 
detection system was used for visualization.   
Antibody specificity was tested with a c-FLIP blocking peptide (2/18; Abcam) according to 
the manufacturer’s protocol. Anti--tubulin mouse monoclonal antibody was served as 
loading control.  
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3.8. Statistical analysis 
In all papers, with the exception of paper III, statistical analysis was performed using the 
SPSS-PC package (Chicago, IL). Probability of <0.05 was considered significant. In paper I, 
the association between FCM and ICC results was executed using Wilcoxon Signed Ranks 
Test, whereas, the association between the expression of the studied molecules and 
clinicopathologic parameters in papers II, IV, V and VI was performed using the Mann-
Whitney U test. The same test was used in paper II for comparative analysis of receptor 
expression between OC versus breast carcinoma. Paired t test was used in papers II, IV and 
VI for the relationship between the expressions of the studied molecules.  
Survival analysis was performed by using the Kaplan-Meier method and groups were 
compared with the log-rank test. Multivariate survival analysis was executed by using Cox 
proportional hazard model. 
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4. SUMMARY OF PAPERS 
Paper I 
Flow cytometric immunophenotyping of epithelial cancer cells in effusions – Technical 
considerations and pitfalls 
This study focused on optimization of the technique for effusions using a 4-color analysis. 
FCM analysis was performed using antibodies against epithelial and mesothelial markers 
(Ber-EP4 and EMA), CD138 and integrin subunits. The titration of antibodies revealed the 
importance of this procedure prior to use of antibodies for immunophenotyping, since 
applying erroneous antibody dilution may lead to higher background staining and to either 
over- or under-compensation of the fluorescence signals. FCM of frozen vs. fresh specimens 
and the performance of FCM compared to immunhistochemistry were evaluated. FCM 
optimization was achieved and applied to clinical specimens, with resulting detection of 
epithelial markers and adhesion molecules on cancer cells. Frozen clinical specimens and cell 
lines showed reduced CD138 expression compared to fresh specimens, with conservation of 
the remaining epitopes. FCM generally showed comparable performance to 
immunhistochemistry. 
 
Paper II 
Death receptor expression is associated with poor response to chemotherapy and shorter 
survival in metastatic ovarian carcinoma  
In this study, we analyzed death receptor expression in malignant effusions (95 OC and 9 
breast carcinoma effusions). Viable tumor cells were analyzed for DR4, DR5, Fas, TNFR1 
and TNFR2 expression using FCM. In addition, twenty primary ovarian carcinomas were 
studied. Results were analyzed for association with clinicopathologic parameters, 
chemotherapy response and survival. DR4, DR5 and Fas were expressed by the majority of 
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specimens, with less frequent expression of TNFR1 and TNFR2. OC in effusion had 
significantly higher Fas expression than breast carcinoma specimens (p=0.047), with non- 
significant differences for the remaining 4 receptors. As in effusions, primary OC showed 
frequent expression of DR4, DR5 and Fas, with infrequent expression of TNFR1 and TNFR2.  
In OC, DR4 (p=0.005) and TNFR2 (p=0.041) expression was higher in FIGO stage IV 
compared to stage III tumors. Effusions from OC patients who responded poorly to 
chemotherapy administered at disease recurrence had significantly higher DR4 (p=0.006), 
DR5 (p=0.01) and Fas (p=0.001) expression. In univariate survival analysis for OC patients, 
higher DR4 expression correlated with poor progression-free (p=0.0411) and overall survival 
(p=0.0352). DR4 expression in both cell populations was found to be an independent 
predictor of overall survival (p=0.008) and progression-free survival (p=0.003) in multivariate 
Cox analysis. 
DR expression in tumor cells in effusions was frequently observed in both OC and breast 
carcinoma. The association of DR expression with advance stage, poor response to 
chemotherapy and poor survival may suggest that cancer cells in effusion are protected from 
DR-induce apoptosis and these molecules are linked to aggressive clinical course in 
metastatic OC. 
 
Paper III 
Methods for simultaneous measurement of apoptosis and cell surface phenotype of 
epithelial cells in effusions by flow cytometry 
The objective of this study was to establish a FCM assay for detection of epithelial cells in 
effusion combined with quantification of apoptosis. The assay consisted of following stages: 
culturing and induction of apoptosis by staurosporine in control OC cell lines (SKOV-3 and 
OVCAR-8); preparation of effusion samples and cell lines for staining; staining of carcinoma 
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cells in effusion and cell lines using cell surface markers (Ber-EP4, EpCAM and CD45) and 
intracellular/nuclear markers of apoptosis (cleaved caspase-3 and caspase-8, and incorporated 
deoxyuridine triphosphates; dUTP); and FCM analysis of cell lines and effusion specimens. 
Cell lines treated with staurosporine underwent apoptosis, evidenced by considerable higher 
expression of the apoptotic markers compared to control cell lines. Carcinoma cells in 12 
effusion specimens were differentiated from leukocytes applying the epithelial markers Ber-
EP4 and EpCAM and leukocyte marker CD45, whereas mesothelial cells were excluded 
through the absence of expression of epithelial markers. Low percentage of apoptotic 
carcinoma cells in effusion specimens was observed. 
 
Paper IV 
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma 
effusions using the Annexin V/7-AAD assay 
This study investigated Annexin V expression in 76 OC effusions using FCM. Results were 
analyzed for association with clinicopathologic parameters and survival. In addition, Annexin 
V expression was compared with the previously-studied apoptotic markers (cleaved caspase-3 
and caspase-8 and dUTP incorporation). Annexin V was detected in all specimens and the 
expression was significant higher compared with cleaved caspases and dUTP incorporation 
(p<0.001). Annexin V expression was higher in grade 3 tumors compared to grade 1-2 tumors 
(p=0.014). In postchemotherapy specimens, higher Annexin V expression significantly 
correlated with shorter OS (p=0.005) and progression free survival (p=0.013). The data 
presented in this study document Annexin V expression in OC cells effusions. The higher 
Annexin-V expression compared with cleaved caspases and dUTP incorporation may suggest 
that PS surface exposure may be involved in cellular processes other than apoptosis. 
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Paper V  
Measurement of apoptosis in cytological specimens by flow cytometry: comparison of 
Annexin V, caspase cleavage and dUTP incorporation assays 
The aim of this study was to compare the performance of different assays for measuring 
apoptosis in cytological specimens by flow cytometry. Apoptosis was investigated in 27 (22 
effusions and five fine needle aspirates) specimens consisting of 20 malignant and 7 reactive 
specimens. The detection of malignant cells was confirmed in all 20 specimens using Ber-
EP4, EpCAM and EMA. Wide variation in the degree of apoptosis was detected in both 
malignant and reactive samples applying all assays. However, the percentage of Annexin V-
positive cells was higher compared with those showing caspase cleavage and dUTP 
incorporation in most cases, irrespective of specimen type. Both malignant cells and reactive 
mesothelial cells in pleural effusions had significant lower expression of dUTP incorporation 
compared with their counterparts in peritoneal specimens (p=0.001). The results of this study 
were in concordance with our previous observation in OC effusions, that measurement of 
apoptosis applying the Annexin V assay gives higher expression value than those obtained 
using the cleavage caspase and dUTP incorporation assays, suggesting that this assay may not 
accurately reflect the degree of apoptosis in both reactive and malignant cells in effusions. 
 
Paper VI  
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian 
carcinoma effusions 
In this study, a FCM protocol for detection of c-FLIP in serous effusion specimens was 
established. Additionally, the clinical relevance of c-FLIP expression and the potential 
association with previously studied parameters such as DR, cleaved caspases and dUTP 
incorporation was studied. The procedure consisted of following steps: two c-FLIP antibodies 
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were tested in four different cell lines of OC (SKOV-3, OVCAR-3 and OVCAR-8) and MM 
(MSTO-211H) origin using Western blotting and the best performing antibody was used for 
titration of c-FLIP expression in a panel of five cell lines consisting of OC, breast carcinoma 
(T47-D) and MM. The concentration that provided the best discrimination between signal and 
noise was applied for comparison of the performance of three fixation and permeabilization 
protocols. The best performing protocol was used for analysis of 69 OC effusions. c-FLIP 
expression was analyzed for association with clinicopathological parameters and survival. 
Rabbit polyclonal c-FLIP by Abcam and the IntraStain kit by Dako provided the best results. 
c-FLIP expression was observed in tumor cells in all 69 effusions. No association was found 
between c-FLIP expression and clinicopathologic parameters, including chemoresponse and 
survival. However, an inverse correlation was found between c-FLIP levels and expression of 
the previously studied apoptosis marker cleaved caspase-3 (p=0.029). An assay for measuring 
c-FLIP in cytology specimens is presented. c-FLIP is frequently expressed in OC effusions, 
but its expression appears to be unrelated to disease aggressiveness. 
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5. RESULTS AND DISCUSSION 
5.1. The problem 
Serous effusions are a common finding in patients suffering from advanced cancer, including 
AC of the lung, ovary, breast, and gastrointestinal tract, MM and primary peritoneal 
carcinoma, for whom the odds of getting cured by conventional treatment are low (84). This 
highlights both the significance of strengthening early detection and the call for developing 
targeted therapy approaches, such as characterization of the anti-apoptotic, survival and drug 
resistance mechanisms of the tumor cells in both effusion and primary tumor (84,156).  
As aforementioned, FCM has the potential for quantitative measurement of molecules 
involved in a range of biological processes such as proliferation, adhesion, apoptosis, cellular 
metabolism and intracellular signaling, as well as molecules related to chemotherapy response 
and prognosis in advanced and/or recurrent cancer. In the analysis of leukemia and 
lymphoma, a number of consensus proceedings have been established (2,297,298).  
However, the use of this technology in diagnosis and clinical research of effusion cytology 
still requires improvement in way of optimization and calibration due to the different 
characteristics of metastatic AC cells, MM cells and lymphoid cells.   
 
In this thesis, we optimized the technical aspects of FCM by focusing on issues such as 
instrument settings, antibody titration, panel selection, specimen handling/storage and fixation 
and permeabilization to characterize carcinoma cells in effusion. Furthermore, we studied 
molecules involved in cell survival and in the apoptotic process and the molecular differences 
between metastatic OC, breast carcinoma and MM in effusions. We additionally analyzed the 
anatomic site-related expression and clinical role of these proteins. 
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5.2. The technical aspects of FCM in analysis of effusion specimens 
FCM has become an essential laboratory technique in many clinical and research institutions. 
In hematological malignancies it is widely used to diagnose leukemia and lymphoma (1,2, 
297,298). Recently, other diagnostic and research applications of multiparameter FCM have 
been explored (84,120-127,299-304). FCM is able to provide statistical accuracy, 
reproducibility and high sensitivity and allows simultaneous measurement of several 
constituents on a cell-to-cell basis. The main disadvantages of FCM are the lack of 
morphological visualization and structural information that solid tissue samples can provide. 
Furthermore, the technical considerations of FCM immunopheotyping are defined by 
components such as 1) careful sample handling, storage and preparation; 2) quality control of 
all staining and instrumentation protocols; 3) antibody titration, appropriate intracellular 
staining reagents; which are essential for high-quality multicolor FCM analysis 
(297,298,305,306).  
 
5.2.1. Sample handling, storage, and preparation 
Unlike blood samples, collection of effusion specimens involved more radical procedures 
with more patient discomfort than venopuncture. Thus, these specimens are considered as 
valuable diagnostic and research material and specimen flagging criteria related to the 
condition or appearance of the specimen may be used prior to rejection as unsuitable material 
(297). In our laboratory, effusion specimens containing few malignant cells (<5%) will not be 
considered as suitable for FCM. Crucial for all specimens submitted to FCM analysis is the 
preparation of single cells in suspension. The aim is to increase the yield of cells of interest 
while sustaining the integrity of cellular structure and antigenicity. The dissociation or 
separation of cells can be performed using different methodologies, including mechanical or 
enzymatic dissociation (297,307). Nevertheless, it should be noted that enzymatic cell 
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dissociation may results in some degradation of surface proteins and glycoproteins. Thus, 
enzyme-free or mechanical cell dissociation is occasionally preferable in preserving the 
structural integrity of membrane surface proteins for FCM analysis (307). However, for 
effusion specimens this is a minor issue since most effusion specimens contain single cells, 
the exception being when effusion specimens contain cells in small clusters, in which case 
mechanical dissociation applying a 70m nylon filter is performed. This method is preferable 
since it is easy and rapid to perform without destroying cell integrity. In addition to cancer 
cells, effusion specimens may contain various cell populations including leukocytes, 
erythrocytes and RM cells. Although multi-color FCM provides the opportunity to analyze 
heterogeneous cell populations, it is frequently desirable to purify cell populations prior to 
FCM analysis. While the removal of leukocytes by density gradient centrifugation is no 
longer necessary, current FCM technology requires elimination of erythrocytes using different 
lysis methods (308). The lysis of erythrocytes in effusion specimens in our laboratory was 
performed using lysis buffer containing ammonium chloride, which does not affect the 
staining pattern in other cells. Importantly, the loss of cells of interest during sample 
preparation should be minimized.  
 
Cryopreservation of ovarian tissue, oocytes, human embryos and hematopoietic cells using 
well recognized technologies that allow banking and safe recovery of tissue and cells have 
been reported (309,310). During cryopreservation cells suffer widespread physical and 
biological stresses. However, its application has an important role in basic and clinical 
sciences (311). The upper time limit for effusion specimen preservation has not been defined, 
but seems to be dependent on the nature of the specimen and the conditions in which the 
specimen is kept. Ideally, fresh effusion specimens should be processed and stained for FCM 
analysis immediately after collection. However, due to a busy hospital setting, 
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cryopreservation of effusion specimens provides practical advantages in terms of operator-
dependent variability and use of the same antibody batch for analysis. In addition, valuable 
material may be aliquoted and is thereby available for further research. Selection of the 
appropriate procedures for sample handling, storage, and preparation depend on the cell 
parameters being analyzed (e.g., protein, DNA, or RNA) and the localization of the markers 
(e.g., cell surface, cytoplasm, or nucleus) (306). Choosing the appropriate procedure is 
essential for high-quality FCM analysis. The main drawbacks of cryopreservation are that 
they may result in cell loss and damage of epitopes leading to reduction and sometimes 
abolishment of reactivity for many antigens (306). Several studies have investigated the 
impact of cryopreservation on the cellular phenotype, survival, proliferation and 
differentiation on both hematological and nonhematological cell populations (312-318). 
However, the reported data are inconsistent. Some studies have suggested that 
cryopreservation of cells may effect the biological function of cells. One study showed that 
telomere shortening and cellular senescence in cryopreserved cells may be the consequence of 
the increase in single-strand breaks in telomeric DNA (314). Two other studies demonstrated 
that cryopreservation induces profound decrease of CD62L expression on the surface of 
CD34+ cells and of CD4+ and CD8+ T lymphocytes (312,313). Terry et al. demonstrated that 
the process of cryopreservation leads to decreased attachment efficiency of human 
hepatocytes, due to the significant downregulation of cell adhesion molecules including 
integrins, cadherins, catenins, and matrix mellaproteinases in the cultured cryopreserved 
hepatocytes compared to fresh hepatocytes (315).  
Only one study has assessed the effect of cryopreservation on the cellular phenotype in 
cytological specimens (316). This study evaluated a method for long-term storage of 
cytological specimens at -70°C and found no significant differences in preservation, 
cellularity and staining intensity with PAP or Diff-Quik stains between fresh and frozen 
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specimens, with the exception of normal and malignant lymphocytes showing poorer 
preservation in frozen state. The reactivity for mucin and immunochemical stains was 
identical in fresh and frozen preparations, with the exception of -glucuronidase and CEA 
staining, the former being negative in frozen specimens and the latter absent in fresh samples 
(316). In another study, the cell suspension from fresh tissue specimens was divided in four 
aliquots and FCM analysis was performed on fresh cells, cells in 50% methanol at 4°C, cells 
in buffer after formalin fixation at 4°C and cells cryopreserved at -70°C. The authors 
demonstrated that cryopreservation was the best method for preservation of oncoproteins and 
that there was a good correlation between oncoprotein expression and the quality of the DNA 
histograms (300). Additional studies have shown that cryopreservation of human adipose-
derived stem cells under standard 10% DMSO procedure has no impact on the phenotype, 
proliferation or osteogenic differentiation of the cells (317,318). 
The protocol for cryopreservation of cell lines and clinical specimens applied in paper I 
resulted in similar expression of the surface markers Ber-EP4, EMA, CD15 and 6, V, 
1(C29) integrin subunits in fresh and frozen conditions for both cell lines and clinical 
specimens. The exception was CD138 (syndecan-1), which was lost or reduced in frozen 
MDA-MB-231, SK-BR-3, T47-D, NCI-H520 cells and in clinical specimens. Tests in our 
laboratory have shown that cryopreservation of cells in liquid nitrogen resulted in better 
CD138 antigen preservation, with no significant differences observed regarding the other 
markers. Taken together, these results highlight the importance of correct handling and 
storage of specimens prior to FCM analysis. 
                                                                                                                                                                          
5.2.2. Optimization of the instrument settings 
To guarantee adequate performance of the flow cytometer for any given application, the 
instrument and instrument settings must be properly set up and the measurement of 
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fluorescence intensity must be validated (297). This can be accomplished by using a range of 
commercially available standards counting microbeads and cellular control materials, which 
has been pivotal in reaching this purpose (319,320). Two sets of protocols can be carried out 
in order to ensure optimal instrument performance. The first set of protocols including an 
examination of the efficiency and performance of the lasers, optical filters, amplifiers and 
PMTs is performed by service personnel, whereas the second set of protocols consists of 
frequent monitoring of instrument set-up and performance by the operators to identify 
problems and variations (297,321). Optimal instrument settings entails that all cellular 
populations are observable on each FL or light scatter channel. This procedure is performed 
by applying a representative stained cell line or cell specimen (297). Correction or 
compensation of emission spectra overlap is of the utmost importance for proper data 
analysis. It is vital to understand the effects of different types of errors regarding 
compensation in order to recognize the inherent limitations of the data, as well as how these 
limitations might be dealt with by changes in experiment design (322). Several approaches for 
multicolor compensation based on hematopoietic cell populations have been described 
(16,17,323-325). In paper I, however, due to the different characteristics of epithelial cells 
regarding cell size, cell complexity and autofluorescence background compared to 
hematopoietic cell populations, the PMTs and instrument settings were optimized using a 
single-stained mixture of T47-D/PBL for detection of the cells of epithelial origin. The 
subtraction of unwanted contribution of fluorescent light from a dye with an overlapping 
emission spectrum was performed using electronic hardware subtraction. The compensation 
was carried out using fluorochrome (FITC, PE, PerCP and APC)-labeled monoclonal 
antibodies and the spectral characteristics of these fluorochromes are quite stable and alike. 
Thus, the same voltages for PMTs were applied throughout the thesis. 
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Most of the FCM instruments provide pairwise compensations. The flow cytometrer applied 
in the thesis allows pairwise compensation and although successful for the compensation 
settings in paper I, this strategy becomes increasingly complicated as the number 
fluorochromes increases or tandem dyes are used and may lead to artifactual data and 
misinterpretation (16,323,326,327). These problems can partly be solved by software 
compensation, when the data are collected uncompensated, providing the flexibility of setting 
proper compensation every time for every specimen (326). However, software compensation 
strategies also encounter problems as discussed by Roederer (322) and Stewart et al. (326). In 
recent years, remarkable advances in FCM technology regarding hardware, software tools, 
instrument calibration and quality control kits made it more convenient to perform instrument 
calibration and to measure as many as 20 independent parameters on each cell (328). 
 
5.2.3. Antibody titration and cell fixation and permeabilization 
The antibody titration assay is crucial prior to immunophenotyping, and several reports 
addressing this concern and providing guidelines have been published (298,329,330). When 
applying an antibody, titration assay is essential to optimize the amount and concentration of 
the antibody in order to reduce nonspecific antibody binding. The purpose of an antibody 
titration assay is to determine an appropriate antibody concentration resulting in the highest 
signal of the positive cell population and the lowest signal of the negative cell population 
(298,329,330). Sensitivity of a reagent determined by factors such as the cell´s 
autofluorescence in the region of the spectrum, the performance of the antibody conjugate and 
the presence of other antibody conjugates attached to the same cell are important to consider 
when developing multicolor antibody panels (331). The chosen panel(s) of antibody 
conjugates must be validated. First, the spectral overlaps of the chosen of antibody conjugates 
should be satisfactorily controlled. A preferable antibody conjugate to detect antigens 
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expressed at low intensity is PE due to its high quantum yield and lack of interference by 
cellular autofluoresence. Second, steric hindrance should be minimized or eliminated between 
the antibodies in each cocktail. Thus, the antibodies in combination should provide the same 
intensity as that obtained in single-color assay. Last, the volume of the antibody used for 
staining must be validated for the staining procedure and type of specimens used.  
An increase of fluorescence intensity in negative cells, which are not supposed to express the 
antigen of interest, is generally due to nonspecific antibody binding. When negative cells 
show an increase of nonspecific antibody binding, it is likely that it also occurs additionally to 
the expected specific binding on positive cells. From the results in paper I, using an excess 
amount of an antibody may lead to increase in background staining or nonspecific antibody 
binding resulting in imprecise compensation and reduce sensitivity in a multicolor analysis 
(331,332). In paper VI, we observed that the antibody from Santa Cruz Biotechnology 
generated the highest S/N ratio at the concentration of 4g without reaching an optimal 
antibody concentration plateau in all cell lines but one (T47-D) (data not shown). The optimal 
concentration of this antibody may be even higher than 4g. The antibody from Abcam 
demonstrated an optimal antibody concentration plateaus at 2.5g for all cell lines. Exclusion 
of an antibody from the study panel should be considered when the concentrations of the 
antibody are too high without reaching an optimal antibody concentration plateau, possible 
due to low affinity and specificity of the antibody. 
 
In paper I and VI, titration results revealed that some vendors provide antibodies at higher 
concentrations than stated, whereas others provide antibodies below titer. In addition, in paper 
VI, validation of specificity of a marker to the condition of the material prior to 
immunophenotyping was performed by Western blotting. 
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The protocols for intracellular antigen detection have their own limitations and challenges as 
compared with those used for surface antigen detection. Procedures for staining of surface 
antigens have been successfully standardized. However, it is evident that no single method is 
proper for staining of all intracellular antigens. Several aspects including knowledge of 
antigen location, selection of fixative and permeabilization reagents, antibody specificity, 
fluorochrome selection and use of adequate controls need to be considered when approaching 
the development of an intracellular staining method (333). At present, several protocols for 
detection of intracellular/nuclear antigens have been described (333-340). Intracellular 
labeling of cells is accomplished by fixation and permeabilization to allow passage of the 
antibodies into the cytoplasm and nucleus without destroying the structural integrity of the 
cells. Awareness of the effects of various reagents used for fixation and permeabilization, as 
well as conditions that may be harmful for one parameter while being optimal for others is 
crucial (297). Fixatives can be divided on the basis of their cross-linking or coagulant 
characteristics. Cross-linking fixatives such as paraformaldehyde have been widely used in 
the targeting of intracellular antigens and have been reported to reliably anchor and stabilize 
most antigens, hence preventing loss of antigens after addition of permeabilzation agents and 
therefore making it generally the fixative of choice (333). The selection of the fluorochomes 
and the antibodies is very important. For membranous labeling of cells, a fluorochrome must 
not be altered by subsequent fixation and permeabilization. For intracellular staining, the size 
of a fluorochrome is important to ensure proper penetration of the conjugated antibody 
through the cell membrane to the target antigen. In paper III, we observed degradation of the 
fluorochrome PerCP but neither PE nor APC conjugated to CD45, a marker already bound to 
the cell surface, by ethanol fixation, resulting in lost detection. The fluorochrome PerCP, 
which is a natural light-harvesting carotenoid-protein complex, is probably more sensitive to 
ethanol denaturation than PE or APC. In paper VI, the low S/N ratio using Fix & Perm kit 
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compared with IntraStain kit and formaldehyde/Triton X-100 fixation and permeabilzation 
method may be explained by decreased of fluorescence signal of the investigated marker or 
increased of baseline auto-fluorescence. Furthermore, the formaldehyde/Triton X-100 fixation 
and permeabilzation method induced significant modification on light scatter properties 
resulting in formation of cell debris. On the contrary, the IntraStain kit induced only minor 
decreased in both FSC and SSC without causing loss of resolution or problems related to 
analysis. The result using the formaldehyde/Triton X-100 fixation and permeabilzation 
method may be a consequence of using a higher concentration of paraformaldehyde than 4%. 
It has been shown that using too concentrated cross-linking agent, extensive cell clumping 
may occur (334). In addition, the use of Triton X-100 as a permeabilizing agent has been 
reported to induce dramatic alteration in FSC/SSC parameters, making it difficult to 
distinguish lymphocytes from monocytes, as well as dead cells from live cells (337). These 
changes on light scatter properties as well as the increase of baseline auto-fluorescence have 
been reported by other investigators (333-340). The cause of autofluorescence using 
paraformaldehyde as a fixative may be that this agent reacts with a variety of free amine 
groups producing fluorescent product (340). Washing out the fixative and storing the 
specimens in buffer may reduce the increase in autofluorescence (336). In paper III and VI, 
washing out the fixative reduced but did not remove the increase in autofluorescence.  
 
5.3. The biological role and clinical relevance of DR expression in OC effusions 
Activation of DRs has been shown to promote both cell death and cell survival and 
proliferation (158-160,163-166,170-172).  
 
The results in paper II showing that DRs expression in OC cells is associated with poor 
response to chemotherapy and poor survival may suggest that malignant ascites from OC 
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patients protects OC cells from DR-induced apoptosis and that these receptors may otherwise 
promote cell survival. This notion is supported by Lane et al. showing that some OC ascites 
specimens inhibit TRAIL- and FasL-induced apoptosis in vitro and that the prosurvival 
activity was dependent upon the activation of Akt (183). In another study, the same group 
demonstrated that malignant ascites from OC patients protects OC cells from TRAIL-induced 
apoptosis through Akt activation in an v5 integrin-dependent pathway (202). Further 
evidence of the involvement of DRs in OC progression is the finding that autocrine 
production of TNF- by OC cells isolated from malignant ascites generates a network of 
growth factors that may act in an autocrine and paracrine process to promote tumor growth 
(203,204). Although both Fas and sFas were highly expressed, primary OC cultures were 
more resistant to Fas-mediated apoptosis compared to their normal counterparts (186), and 
OC ascites showed the highest level of Fas compared to primary and recurrent solid 
specimens (341). 
 
The addition of ascites from a cohort of 35 OC patients to the cancer ovarian cell line CaOV3 
increased TRAIL IC50 in vitro and patients in the group with higher IC50 was associated with 
shorter disease-free survival (342). In other studies, DRs or ligands have been shown to be 
associated with outcome in OC patients. In one study, the inhibitory effect of OC ascites was 
associated with platinum resistance (343). In another study, the authors found that high level 
of DR5 was correlated with less favorable prognosis in cancer patients with invasive and 
grade 3 tumors (192). Tumor microenvironment-related factors, including cytokines and 
hypoxia, have been shown to modulate the response of cancer cells to TRAIL (344,345). 
Taken together, OC cell survival in the peritoneal cavity despite chemotherapy may be due to 
the action of anti-apoptotic factors and/or growth factors in ascites that support tumor growth 
and progression, hence causing tumor relapse.  
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5.4. DR as therapeutic targets 
Various stimuli such as growth factor withdrawal, UV light, irradiation or chemicals can 
induce apoptosis. The latter two have been intensively used in cancer therapy (133,147). A 
main factor in stress-induced apoptosis through the intrinsic pathway is the activation of p53 
(147). Cancer cells can obtain resistance to apoptosis by a variety of mechanisms that 
interfere at different levels of apoptosis signaling. The inactivation of p53 is commonly found 
to confer cancer cell resistance to conventional therapy (147). Hence, in order to bypass the 
need for p53 intact signaling, extensive efforts have been focused on the development of new 
therapeutic strategies targeting DRs for cancer therapy (346,347). The treatment strategy 
applying systemic administration of TNF and FasL has been evaluated, but its use has been 
hampered by undesirable toxic effects to normal tissues (348,349). TNF- has been shown to 
be an efficient anticancer agent in several in vitro and in vivo preclinical studies. However, the 
use of systemic TNF- has been limited due to the toxic side effects and lack of efficacy at 
maximum tolerated dose. Nevertheless, the combined use of TNF-  and chemotherapy in the 
isolated limb perfusion setting appears to be of clinical value due to its direct anti-
proliferative effect of TNF- and the capacity to enhance drug diffusion into tumor tissue 
(350). 
 
Preclinical studies investigating the therapeutic role of recombinant TRAIL have shown its 
capacity to induce apoptosis in various tumor cell lines and xenografts, while lacking toxic 
effects on most normal cells (351,352). Lately, recombinant TRAIL has been used in clinical 
trials for the treatment of a variety of malignancies (353,354). While, results from phase I and 
II studies may suggest tolerated toxicity, the therapeutic efficacy has been limited (352). In 
addition to most of the current clinically used chemotherapy agents such as cisplatin, 
doxorubicin, 5-fluorouracil and camptothecin, various TRAIL and chemotherapy 
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combinations have been demonstrated to synergistically enhance TRAIL-mediated apoptosis 
(175,181,187-190,351,352). The possible values of TRAIL-induced apoptosis as an 
anticancer modality have been further indicated by its capacity to improve the efficiency of 
radiotherapy (351,352). Hence, TRAIL-driven DR activation may have great potential as a 
modality for cancer treatment. 
 
Monoclonal antibody technology has been shown to be a potent therapeutic agent for cancer 
treatment. Preclinical studies have demonstrated the possible application of agonistic 
monoclonal antibodies against DR4 and DR5 for cancer therapy. The use of agonistic 
antibodies may have greater therapeutic potential than TRAIL due to specific targeting of 
DRs without decoy receptor binding. In addition, TRAIL has a much shorter plasma half-life 
in vivo compared with monoclonal antibodies (351,352). The results of monoclonal antibodies 
against DR4 (Mapatumumab, HGS-ETR-1, TRM-1) and DR5 (Tigatuzumab, CS-1008, 
Lexatumumab, HGS-ETR-2, Conatumumab, AMG 655, 4H6, Apomab) currently in phase I 
and II clinical trials indicate some anti-tumor activity, have a good safety profile and appear 
to be well-tolerated (161,351,352). 
Although previously published data and the results from paper II may suggest that TRAIL 
sensitivity is altered in some OC (180,193,194), recent data have shown that agonist 
monoclonal antibody (TRA-8) against DR5 induces dose-dependent cytotoxicity in most of 
ovarian tumors in an ex vivo model. Furthermore, the combined use of TRA-8 and 
chemotherapeutic drugs increased the cytotoxicity (355,356). 
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5.5. Detection of apoptosis in malignant and reactive cytological specimens 
In paper III, we have developed a FCM assay quantifying cleaved caspase-3, 8 and DNA 
fragmentation in apoptotic OC cells in effusion specimens (discussed in section 3.5). This 
assay was applied in paper V.  
Based on the level of cleaved caspase-3 and -8 and dUTP incorporation, the results in paper V 
demonstrated that both cancer cells and RM cells in effusions undergo little apoptosis. These 
results are in agreement with our previous findings in the analysis of OC effusion specimens, 
in which detection of cleaved caspase-3 and -8 and dUTP incorporation was less than 10% of 
OC cells in the majority of specimens (357). Further support of the results is the observation 
that p85-PARP, the product of PARP cleavage by active caspase-3, is expressed in only 0-5% 
of OC cells in most of the cases (358). No significant differences in the levels of activated 
caspases and dUTP incorporation were observed in malignant and reactive specimens. This 
may indicate that RM cells in effusions are sentinel cells that can sense and respond to signals 
within their microenvironment in order to adapt, proliferate and undergo changes such as 
epithelial-mesenchymal transition, which is a unique feature of cancer cells (359).  
 
5.6. Annexin V expression is not a sign of apoptosis, and is associated with poor 
differentiation and prognosis 
Certain conditions such as blood coagulation, cell clearance, immune regulation and apoptosis 
(240-244) may induce translocation of PS on the cell surface and can be detected by its 
binding to the protein annexin V (257,258). In paper IV and V, we analyzed PS expression in 
OC effusion specimens and malignant and reactive cytological specimens, respectively. In 
both studies, we found significantly higher annexin V expression compared to other apoptosis 
parameters such as cleavage caspases and dUTP incorporation in most of cases, regardless of 
specimen type. These findings are in agreement with other studies showing higher fraction of 
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hematopoietic cancer cell lines expressing annexin V compared with those positive for the 
TUNEL assay, the Apo2.7 assay (detecting the exposure of the mitochondrial membrane 
protein 7A6 antigen on the cell surface) or the DNA fragmentation assay (360,361). 
 
Elevated PS externalization on the cell surface is not inevitably activated and controlled by 
the apoptotic regulatory machinery (362,363). The authors further demonstrated that PS 
exposure is inducible, reversible, and independent of cytochrome c release, caspase activation 
and DNA fragmentation (363). Furthermore, PS exposure can be observed in nonapoptotic 
cells, including erythrocytes, activated platelets, erythroid precursors, and undifferentiated 
tumor cells as well as in cancer cell lines derived from different cancer types such as 
malignant melanoma, prostate carcinoma, renal carcinoma, glioblastoma and 
rhabdomyosarcoma (241,245-247,249). PS has additionally been reported to be a constituent 
in membrane vesicles shedding from practically all cell types and are involved in 
physiological and pathological processes including tumorigenesis (364). Other investigators 
have demonstrated that PS exposure can occur in a reversible manner under conditions of cell 
stress that do not necessarily obligate a cell to undergo programmed cell death (365-367). 
These studies revealed that PS externalization could be detected in cells with no other 
morphological features of apoptosis. In addition, the levels of PS exposure may be reversible 
on withdrawal of apoptotic stimulus (365-367).  
 
In paper IV, high annexin V expression was correlated with poor differentiation and prognosis 
in postchemotherapy effusion specimens. We do not attribute this finding to mechanical PS 
exposure, since cells in effusions do not undergo this procedure. Furthermore, our clinical 
findings, together with the abovementioned studies, may suggest that PS exposure on cancer 
cells is not a general feature of apoptosis (249,367), but may drive the course of tumor 
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progression by stimulating a number of anti-inflammatory responses, inducing a state of 
immunosuppression and the release of transforming growth factor (TGF)-1, an essential 
mediator of the process of malignant progression (241,247,364,368). Cancer cells have been 
shown to be able to produce non-physiological levels of TGF-1 in an autocrine and a 
paracrine manner, effecting the tumor environment, contributing to tumor progression and 
metastasis (369). Lima et al. demonstrated elevated production of PS-containing tumor-
derived microvesicles in vitro by the highly metastatic melanoma cell line B16F10, and these 
vesicles increased TGF-1 production by cultured macrophages and, in vivo, enhanced the 
metastatic potential of B16F10 cells in mice (370). Additional evidence is the observation that 
formation of membrane vesicles containing PS is associated with the tumor phenotype, as 
evidenced by the higher amount of microvesicles found in the fluids of cancer patients 
compared with healthy persons (371,372). Further support of the notion that PS translocation 
to the outer leaflet of the cell membrane is not a sign of apoptosis is the low level of apoptotic 
cells detected by the TUNEL and cleavage caspases assays in paper V and in our previous 
study (357). In contrast, our previous study of the same cohort demonstrated that high cleaved 
caspase-3 expression was beneficial for patient survival, indicating that PS exposure may 
promote OC cell survival (357). Other studies on the prognostic value of PS exposure in OC 
specimens are not available. However, some reports have proposed PS cell surface expression 
as a potential diagnostic marker, as well as target for cancer therapy (249,250). Taken 
together, the results in paper IV and V indicate that the annexin V assay may not be a reliable 
method for apoptosis measurement. 
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5.7. c-FLIP is frequently expressed in OC effusions, but is unrelated to 
clinicopathological parameters and survival 
The DR signaling pathway is regulated by inhibitor proteins such as c-FLIP, which is one of 
the key determinants of resistance to DR-mediated apoptosis (216-218).  
 
Expression of c-FLIP was detected in OC cells in all effusion specimens analyzed in paper 
VI. We found no association between c-FLIP expression and clinicopathologic parameters, 
including chemotherapy response and survival. Search for studies regarding the clinical role 
of c-FLIP expression in OC effusions did not identify any previous publications. Some data 
are available, though, for primary OC, and the results are inconclusive with respect to its 
clinical relevance (180,191,239). In two reports, no association between c-FLIP expression 
and survival was observed (180,191), whereas in one study combined expression of p53 and 
c-FLIP was associated with poor PFS and OS compared to lack of expression of both 
markers. c-FLIP was an independent prognostic marker in multivariate analysis (239).  
 
Elevated expression of c-FLIP has been found in a number of different cancers. Studies of cell 
lines have shown increased levels of c-FLIP in ovarian, colorectal, gastric, breast, pancreatic, 
and prostate carcinoma, as well as in melanoma and glioblastoma (373). Reports on primary 
tumor tissues from patients have also shown elevated levels of c-FLIP in malignant cells in 
colorectal carcinoma (225,238), B-cell chronic lymphocytic leukemia (228), bladder 
carcinoma (235), hepatocellular carcinoma (237), cervical carcinoma (374), malignant 
melanoma (375), Burkitt’s lymphoma (376), and head and squamous cell carcinoma (377). 
Analysis of primary tumor cells from cancer patients also confirmed upregulation of c-FLIP 
in melanoma (236), gastric carcinoma (378) and Hodgkin’s lymphoma (379). In most 
malignant tumors, the c-FLIPL isoform was shown to be overexpressed. However, there are 
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some reports demonstrating increased c-FLIPS expression (218,373). Overexpression of c-
FLIP is implicated in TRAIL resistance and chemotherapy resistance, and studies have shown 
that high levels of c-FLIP are associated with unfavorable clinical outcome and may be a 
prognostic factor in cancer (225,229, 235,237,238,374-377). Increased of c-FLIP expression 
has been reported in gastric cancer and was associated with lymph node metastasis, thereby 
possibly contributing to tumor progression (378). c-FLIP was shown to expressed in both 
pancreatic intraepithelial neoplasms and pancreatic ductal adenocarcinomas, but absent in 
normal pancreatic ducts (380). 
 
In paper II, DR expression in OC effusions was associated clinical parameters of aggressive 
disease, including unfavorable PFS and OS. Hence, c-FLIP expression was subsequently 
analyzed for potential association with DR expression. No association was found between c-
FLIP and DR expression. The reason for the lack of association in our studies may be related 
to a small series of matched cases in both studies. Despite the small series, this lack of 
association may suggest that the existence of c-FLIP and DR in effusions is not inversely 
correlated in terms of either expression level or clinical impact. In addition, analysis of the 
association between c-FLIP expression and cleaved caspase-3 and -8 and dUTP incorporation 
(357) in a limited number of matched cases demonstrated inverse correlation between c-FLIP 
and cleaved caspase-3 expression. This may indicate that c-FLIP inhibits apoptotic signaling 
as measured by caspase-3 cleavage.  
 
The above-mentioned studies demonstrate that c-FLIP is often overexpressed in cancer. Thus, 
c-FLIP may be a target for a therapeutic intervention. 
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5.8. c-FLIP as therapeutic target 
There is evidence of strong association between the overexpression of c-FLIP and resistance 
to DR-mediated apoptosis in several human malignancies (373). Resistance was suggested to 
take place at the level of the DISC formation, where the elevated level of c-FLIP expression 
hampers procaspase-8 recruitment and activation (185,218). Overexpression of anti-apoptotic 
proteins in cancer cells suggests they may be targets for anti-cancer therapeutic intervention. 
Indication that DRs could induce resistance to apoptosis was reported (373). Furthermore, 
cancer cells can become resistant to chemotherapeutic agents. However, the combination of 
DNA-damaging agents or metabolic inhibitors such as 5-fluorouracil together with TRAIL 
can bypass this resistance in a variety of tumor cells (373). Therefore, sensitization of cancer 
cells to DR-mediated apoptosis can be accomplished by several stimuli inducing the decrease 
of c-FLIP expression, including antisense cDNA constructs, short interfering RNAs, 
proteasome inhibitors, protein or RNA synthesis inhibitors or chemotherapeutic agents (373).   
 
In OC, c-FLIP expression inhibits the extrinsic pathway in the presence of functional p53 
(185,381). Cisplatin, in particular, has been studied in OC cell lines and found to induce 
ubiquitination and degradation of c-FLIP by enhancing FLIP-p53-ITCH interaction in a 
p53Wt-dependent manner (382). The same investigators demonstrated that ubiquitination of 
c-FLIPS/L was under the control of the Akt pathway (383). Histone deacetylase (HDAC) 
inhibitors, which have been found to regulate c-FLIP levels, may be of potential value in 
cancer treatment. Alterations in histone acetylation patterns in OCs have been observed (154). 
Treatment of OC cell lines with HDAC inhibitors was shown to induce activation of caspase-
9 and -3, leading to apoptotic cell death (384). Treatment with Trichostatin A, a HDAC 
inhibitor, sensitizes OC cells to TRAIL-induced apoptosis by decreasing c-FLIPL expression 
via inhibition of the EGFR pathway, with no impact of c-FLIPS (385).  
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Proteasome inhibitors have been shown to decrease proliferation and induce apoptosis in 
several malignancies (373). PS-341 (bortezomib) has been widely evaluated in different cell 
lines, with different outcome dependent on the type of cell line evaluated. c-FLIP expression 
in chronic lymphocytic leukemia, Burkitt lymphoma, multiple myeloma and esophageal 
squamous cell carcinoma cell lines was decreased after treatment with PS-341 (bortezomib) 
(373). Likewise, studies using MG-132 have shown a decrease in c-FLIP expression in 
chronic lymphocytic leukemia and Burkitt lymphoma cells. The decreased c-FLIP levels were 
associated with upregulation of TRAIL and its DR4 and DR5 (373). In contrast, in OC cell 
lines and OC cells, proteasome inhibitors were shown to exert a considerable pro-apoptotic 
effect and to enhance the sensitivity of cells to TRAIL-induced apoptosis, but this enhanced 
sensitivity was not directly correlated to c-FLIP degradation (386-388). 
Inhibiting translation through RNA interference is regarded as the most specific technique of 
downregulating c-FLIP, and this strategy has been applied in several in vitro studies to 
sensitize cells to TRAIL- or FasL-mediated apoptosis (373). Saulle et al. demonstrated that c-
FLIP knockdown of A2780 and A2780/ADR OC cell lines that express c-FLIP, using a 
specific anti-c-FLIP siRNA significantly reduced c-FLIP expression and clearly enhanced 
TRAIL-induced apoptosis (388). Despite promising results from in vitro studies, there are 
limitations for siRNA in vivo, and clinical trials applying siRNA to target c-FLIP are still not 
initiated (373).  
 
In summary, c-FLIP is an important regulator of DR-mediated apoptosis and uncontrolled c-
FLIP expression is correlated with malignancy in several organs. Thus, monitoring c-FLIP 
expression may be of diagnostic value, and agents that explicitly modify c-FLIP expression 
may be of therapeutic benefit. 
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5.9. The clinical role of cancer-associated molecules in pre- and post-chemotherapy 
effusions 
In addition to comparison of primary tumors, solid metastases and malignant effusions, our 
research group also focuses on the expression and clinical role of cancer-associated molecules 
in pre- vs. post-chemotherapy effusions (84). The expression of cancer-associated molecules 
in malignant cells in pre-chemotherapy samples may characterize the real genetic profile of 
the tumor, since the cells have not yet been exposed to chemotherapy. In contrast, 
modification of cancer-associated molecules in malignant cells in post-chemotherapy effusion 
samples may in fact be related to genetic unsteadiness along tumor progression and 
chemotherapy treatment. 
In this thesis, differences regarding the clinical value in pre- and post-chemotherapy effusions 
were only seen for Annexin V. In paper IV, when patients with pre- and post-chemotherapy 
effusions were analyzed separately, higher than median Annexin V expression in post-
chemotherapy effusions predicted poor OS and PFS survival, with no prognostic value in 
patients with pre-chemotherapy effusions. In our previous study of the same cohort, cleaved 
caspase-3 levels in patients with post-chemotherapy effusions were correlated with improve 
survival (357). This observation is consistent with earlier work from our group showing better 
capacity to predict patient survival found on the expression levels of diverse cancer-associated 
molecules in post-chemotherapy compared to pre-chemotherapy effusions (reviewed in 84). 
The correlation between cancer-associated molecule expression in post-chemotherapy 
effusions, which are normally collected at disease recurrence at the end-time point of PFS, 
and PFS represents retrospective information with respect to disease aggressiveness. On the 
contrary, the correlation between cancer-associated molecule expression and response to 
chemotherapy administered at disease recurrence is a forward estimation of patient outcome. 
Both factors were evaluated in our material. 
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5.10. Apoptosis and cell survival of OC cells in effusions 
Our results in papers II and IV-VI suggest that the aggressiveness of OC cell in effusions 
partly can be explained by aberrant apoptotic machinery and elevated cell proliferation. The 
low level of apoptosis, verification by low expression of parameters of apoptosis, including 
cleaved caspase-3, -8 and dUTP incorporation (357), may be a consequence of blockage of 
DR-induced cell death or the intrinsic apoptotic pathway. This is supported by the frequent 
expression of c-FLIP, an inhibitor of caspase-8 activation at the DISC level, which is 
inversely related to cleaved caspase-3 expression. Further support is the abundant expression 
of XIAP and Survivin, which are potent inhibitors of caspase activity, found in effusion 
specimens by our group (84,156). In another study from our group high level activation and 
expression of NFB p65 in advance-stage OC was observed and nuclear expression was 
associated with poor PFS, supporting its role in cancer cell survival (84,156). 
The findings that DR expression level is a marker of aggressive clinical course and 
chemoresistance may point to the fact that DR signaling is redirected from apoptosis to cell 
survival in OC cells. Furthermore, DR signaling does not only result in activation of effector 
caspases and following apoptosis, but can also stimulate non-apoptotic pathways, including 
activation of NFB, PKB/Akt and MAPKs (389). 
The Annexin V assay is not in concordance with cleaved caspase and dUTP incorporation 
assays in detecting apoptotic cells in effusions, and as apposed to clevead caspase-3, higher 
Annexin V level is correlated with poor PFS and OS, suggesting that PS exposure may be 
involved in cellular processes other than apoptosis.  
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5.11. Technical considerations 
FCM is the main technique applied in this thesis and the attempt to improve multicolor FCM 
for analysis of epithelial cells in effusion was successfully accomplished. However, possible 
limitations and weaknesses of the methodology applied in this thesis must be acknowledged: 
1. Sample handling, storage and preparation. Proper specimen handling is essential to avoid 
induction of artifacts. The effusion specimens in this thesis have been frozen for different 
periods of time, which could affect the final results regarding antigen preservation and cell 
viability. 
2. Selection of antibodies/antibody combinations which are specific and sensitive for FCM 
analysis of carcinoma cells in effusions. The specificity and sensitivity of antibodies vary 
considerably from one manufacturer to another. We attempted to use the best antibodies 
available, but did not test all potential antibodies against each epitope. 
3. Studying single cells in suspension is obligatory for FCM analysis. It may be difficult to 
apply the right cell dissociation method to increase the yield of cells of interest while 
sustaining the integrity of cellular structure and antigenicity.  
4. Relatively small series of cases in some of the studies in this thesis may result in Type II 
error, e.g. in the analysis of the association between c-FLIP, DRs and caspases.  
5. To make the data regarding DR and c-FLIP more robust, additional methods such as IHC 
and WB could have been applied. 
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6. CONCLUSIONS 
1. The attempt to improve the ability of four-color FCM to study cancer-associated molecules 
and parameters related to apoptosis in effusion specimens was successfully accomplished. We 
have further highlighted the importance of correct validation of a new assay by focusing on 
parameters such as instrument settings, antibody titration, antibody panel selection, fixation 
and permeabilization, and specimen handling/storage. 
 
2. High expression of DR4, DR5 and Fas in OC effusion specimens is correlated with poor 
response to chemotherapy at disease recurrence. High DR4 expression in OC effusions is 
associated with poor survival. DRs may mediate cell survival rather than apoptosis in these 
cells. 
 
3. Significantly higher annexin V expression was detected in both reactive and malignant cells 
in effusion specimens compared to cleavage caspases and dUTP incorporation. In OC 
effusions, higher annexin V expression correlated with poor differentiation and poor survival 
in post-chemotherapy patients, whereas cleaved caspase-3 expression was associated with 
improve survival. These findings may suggest that the annexin V is not a specific marker for 
apoptosis measurement, but may have a role in cell survival rather than apoptosis. 
 
4. High c-FLIP expression was found in OC effusions, but was unrelated to clinicopathologic 
parameters and survival. c-FLIP expression is inversely related to cleaved caspase-3 
expression. OC cells in effusions undergo little apoptosis, which may be in part attributed to 
frequent expression of c-FLIP.  
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5. In view of the different expression patterns and clinical role of apoptosis-related proteins in 
OC effusions, the latter may be capable of activating alternative survival pathways, mediating 
the aggressive clinical behavior of this cancer. Thus, apoptosis determination of metastatic 
disease, including OC effusions, may have an important role in monitoring chemotherapy or 
targeted therapy response, stressing the need for trustworthy quantitative apoptotic assays.  
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7. FUTURE PERSPECTIVES 
Over the last few decades, FCM has been established as an important technology in the 
diagnosis of hematological malignancies and has evolved from single-color analysis of 
surface membrane antigens to simultaneous multi-color analyses of surface membrane and 
intracellular/nuclear antigens in cell suspensions. The huge increase in the improvement and 
development of reliable electronics, lasers, fluidics and data analysis software, as well as an 
expanding range of flourochromes, has facilitated the expansion of new FCM applications as 
well as perfection of existing applications. Furthermore, FCM instruments have become more 
user-friendly and less expensive, with an expanding contribution to diagnostic medicine and 
basic biological research. Data from our previous studies and studies in this thesis 
demonstrate the potential of FCM in the diagnosis of effusion specimens and in studying 
cancer-associated molecules, including parameters related to cell proliferation, survival and 
apoptosis, with the aim of better understanding the biological mechanisms that maintain and 
allow cancer cell to survive at this anatomic site.  
 
Technological developments in FCM will go on to give possibilities for increasingly 
advanced analyses of clinical specimens regarding diagnosis and classification of disease, 
prognostication and disease monitoring through and beyond treatment and in cancer research.  
Analysis using multiple parameters simultaneously may be beneficial for unraveling the 
mechanism of action of different cancer-associated molecules and parameters related to OC 
tumor biology in effusion material. Future potential applications of FCM in analysis of 
effusion specimens include validation of gene products obtained by high-throughput analyses, 
quantitative measurement of expression of molecules related to chemotherapy resistance, and 
phospho-FCM decoding of intracellular kinase signaling cascades applying specific 
antibodies which differentiate between the phosphorylated and non-phosphorylated states of 
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proteins as well as particle (microbead)-based FCM assay use to capture the soluble protein 
analyte from the supernatant of effusions.  
An augmentation in the number of parameters is also related with higher demands in 
maintaining a quality system. It is crucial to pay close attention to the many technical aspects 
of FCM that must be mastered in order to produce high-quality results. 
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9. ERRATA 
9.1. Post-submission errata approved by the evaluation committee 
9.1.1. Spelling, grammar, omissions and additions 
Page 63 line 3: “detailed in Table 2” was changed to “detailed in Table 3” 
Page 63 table headline: “Table 2. Cell lines used in the thesis” was changed to “Table 3. 
Cell lines used in the thesis” 
Page 69 line 17: “studied in papers II-V” was changed to “studied in papers III and V” 
Page 69 line 25: “fluorochrome-labeled triphoshodeoxynucleotides” was changed to 
“fluorochrome-labeled triphosphodeoxynucleotides” 
Page 82 line 20: “matrix mellaproteinases at the in cultured cryopreserved hepatocytes” was 
changed to ” matrix mellaproteinases in the cultured cryopreserved hepatocytes” 
Page 95 line 7: ”IV” was changed to ”VI” 
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